



## PWYLLGOR ADNODDAU CYNALIADWY SUSTAINABLE RESOURCES COMMITTEE

<b>DYDDIAD Y CYFARFOD: DATE OF MEETING:</b>	28 June 2022
<b>TEITL YR ADRODDIAD: TITLE OF REPORT:</b>	Finance Report – Month 2 2022/23
<b>CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:</b>	Huw Thomas, Director of Finance
<b>SWYDDOG ADRODD: REPORTING OFFICER:</b>	Rebecca Hayes, Senior Finance Business Partner

**Pwrpas yr Adroddiad (dewiswch fel yn addas)**

**Purpose of the Report (select as appropriate)**

Ar Gyfer Trafodaeth/For Discussion

### ADRODDIAD SCAA SBAR REPORT

#### Sefyllfa / Situation

The purpose of the report, attached at Appendix 1, is to outline Hywel Dda University Health Board's (HDdUHB) financial position to the end of the financial year 2021/22 against the Annual Plan.

The monthly reporting to Welsh Government (WG) is in line with the written report provided to the Sustainable Resources Committee and Board.

#### Cefndir / Background

**Health Board's Financial Plan is to deliver a deficit of £25.0m, after savings of £29.4m.**

#### **Month 2 position:**

- The Month 2 Health Board financial position is an overspend of £4.3m (Month 1, £4.4m), which is made up of £2.2m operational variance and a deficit plan of £2.1m.
- Of the £2.2m overspend in-month, £1.6m relates to undelivered savings plans and £0.6m relates to operational pressures. These pressures are mainly being experienced within our Unscheduled Care teams, but also within Facilities and Radiology.
- The additional costs incurred in Month 2 due to the impact of the COVID-19 pandemic is £3.3m (Month 1, £2.9m). The primary reasons for the increase in COVID-19 expenditure from Month 1 is due to the recognition of an additional WAST discharge support vehicle.
- Confirmation has been received of WG funding to match the costs of the COVID-19 programmes (Tracing, Testing, Mass Vaccinations and PPE; Month 2, £1.6m).
- The Health Board has received initial guidance from WG to assume that funding will be provided to offset the transitional costs of COVID-19 (Month 2, £1.7m) and Exceptional

Energy costs (Month 2, £0.4m); until confirmation is received this presents a risk to the reported position.

### End of Year Forecast

- The Health Board is reporting a financial outturn position of a £42.0m forecast, which is £17.0m higher than the planned deficit of £25.0m. This is due to there being an inadequate level of assurance at this stage around the identification of a further £17.0m of savings schemes deliverable within the current financial year.
- There is a further risk to the current forecast of £42.0m in relation to the operational pressures experienced in Month 1 and 2; as a minimum there is a need to recover the £1.5m operational variation during the remainder of the year, and there is the potential for a continuation of this trend without full mitigation, which at this stage is assessed as c.£11m (inclusive of savings delivery).

### Asesiad / Assessment

The Health Board's key targets are as follows:

- Revenue: to contain the overspend within the Health Board's planned deficit
- Savings: to deliver savings plans to enable the revenue budget to be achieved
- Capital: to contain expenditure within the agreed limit
- PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice
- Cash: While there is no prescribed limit for cash held at the end of the month, WG

encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m.

Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	25.0	4.2	8.7	High*
Savings	£'m	29.4	4.9	1.9	High*
Capital	£'m	29.0	2.0	2.0	Low
Non-NHS PSPP	%	95.0	95.0	n/a	n/a
Period end cash	£'m	4.0	4.0	1.7	High**

\* The Health Board is reporting a financial outturn position of a £42.0m forecast, which is £17.0m higher than the planned deficit of £25.0m. This is due to there being an inadequate level of assurance at this stage around the identification of a further £17.0m of savings schemes deliverable within the current financial year.

\*\* If WG do not fund the cash consequences of the revenue deficit, there is a significant risk to the period end cash position.

### Argymhelliad / Recommendation

The Sustainable Resources Committee is asked to note and discuss the financial position as at Month 2.

Amcanion: (rhaid cwblhau) Objectives: (must be completed)	
Committee ToR Reference: Cyfeirnod Cylch Gorchwyl y Pwyllgor:	4.5 Provide assurance on financial performance and delivery against Health Board financial plans and objectives and, on financial control, giving early warning on potential performance issues and making recommendations for action to continuously improve the financial position of the organisation, focusing in detail on specific issues where financial performance is showing deterioration or there are areas of concern.
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	1371 (score 20) Ability to deliver the Financial Plan for 2021/22 1199 (score 16) Achieving financial sustainability.
Safon(au) Gofal ac Iechyd: Health and Care Standard(s):	5. Timely Care 7. Staff and Resources
Amcanion Strategol y BIP: UHB Strategic Objectives:	All Strategic Objectives are applicable
Amcanion Cynllunio Planning Objectives	All Planning Objectives Apply
Amcanion Llesiant BIP: UHB Well-being Objectives: <a href="#">Hyperlink to HDdUHB Well-being Objectives Annual Report 2018-2019</a>	9. All HDdUHB Well-being Objectives apply

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth: Evidence Base:	Monitoring returns to Welsh Government based on HDdUHB's financial reporting system.
Rhestr Termiau: Glossary of Terms:	BGH – Bronglais General Hospital CHC – Continuing Healthcare FNC – Funded Nursing Care FYE – Full Year Effect GGH – Glangwili General Hospital GMS – General Medical Services MHLD – Mental Health & Learning Disabilities NICE – National Institute for Health and Care Excellence OOH – Out of Hours PPH – Prince Philip Hospital PSPP – Public Sector Payment Policy RTT – Referral to Treatment Time T&O – Trauma & Orthopaedics

	WG – Welsh Government WGH – Withybush General Hospital WRP – Welsh Risk Pool WHSSC – Welsh Health Specialised Services Committee YTD – Year to date
Partion / Pwyllgorau â ymgynhorwyd ymlaen llaw y Pwyllgor Adnoddau Cynaliadwy: Parties / Committees consulted prior to Sustainable Resources Committee:	Finance Team Management Team Executive Team

<b>Effaith: (rhaid cwblhau)</b> <b>Impact: (must be completed)</b>	
<b>Ariannol / Gwerth am Arian:</b> <b>Financial / Service:</b>	Financial implications are inherent within the report.
<b>Ansawdd / Gofal Claf:</b> <b>Quality / Patient Care:</b>	The impact on patient care is assessed within the savings schemes.
<b>Gweithlu:</b> <b>Workforce:</b>	The report considers the financial implications of our workforce.
<b>Risg:</b> <b>Risk:</b>	Financial risks are detailed in the report.
<b>Cyfreithiol:</b> <b>Legal:</b>	HDdUHB has a legal duty to deliver a breakeven financial position over a rolling three-year basis and an administrative requirement to operate within its budget within any given financial year.
<b>Enw Da:</b> <b>Reputational:</b>	Adverse variance against HDdUHB's financial plan will affect its reputation with Welsh Government, Audit Wales, and with external stakeholders.
<b>Gyfrinachedd:</b> <b>Privacy:</b>	Not applicable.
<b>Cydraddoldeb:</b> <b>Equality:</b>	Not applicable.

# Executive Summary

	<b>Health Board's Financial Plan is to deliver a deficit of £25.0m, after savings of £29.4m.</b>
<b>Revenue</b>	<ul style="list-style-type: none"> <li>The Month 2 Health Board financial position is an overspend of £4.3m, which is made up of £2.2m operational variance and a deficit plan of £2.1m; this is after recognising £1.7m of assumed WG transitional funding for COVID-19. £1.0m of savings schemes were delivered in line with identified plans.</li> <li>Of the £2.2m overspend in-month, £1.6m relates to undelivered savings plans and £0.6m relates to operational pressures. These pressures are mainly being experienced within our Unscheduled Care teams, but also within Facilities and Radiology.</li> </ul>
<b>Projection</b>	<ul style="list-style-type: none"> <li>The Health Board has received confirmation of WG funding to match the costs of the COVID-19 programmes (Tracing, Testing, Mass Vaccinations and PPE), and has received initial guidance from WG to assume that funding will be provided to offset the transitional costs of COVID-19 of £16.4m and the Exceptional Energy, Health and Social Care Levy and Real Living Wage commissioned services costs of £12.0m. On this basis, the Health Board is forecasting a financial outturn position of £42.0m, which is £17.0m higher than the planned deficit of £25.0m. This is due to there being an inadequate level of assurance at this stage around the identification of a further £17.0m of savings schemes deliverable within the current financial year.</li> <li>There is a further risk to the current forecast of £42.0m in relation to the operational pressures experienced in Month 1 and 2; as a minimum there is a need to recover the £1.5m operational variation during the remainder of the year, and there is the potential for a continuation of this trend without full mitigation, which at this stage is assessed as c.£11m (inclusive of savings delivery).</li> <li>Of the identified savings schemes of £12.4m, only a small number are currently assessed as recurrent, with a full year effect of £0.5m. There is a significant risk that the underlying deficit of £53.9m will continue if recurrent savings schemes of £28.9m are not identified in-year. Whilst this is an improvement from the 2021/22 position of £68.9m, this presents a challenge to be addressed as part of the revised IMTP based on our Target Operating Model.</li> </ul>
<b>Savings</b>	<ul style="list-style-type: none"> <li>Whilst the focus of the Health Board is on identifying and implementing recurrent schemes, the current combination of capacity and COVID-19 pressures being experienced operationally has diverted significant managerial resource. This has meant that, of the required £29.4m, only £12.4m have been identified, largely on a non-recurrent basis. The unidentified gap of £17.0m has been recognised evenly across the financial year for transparency, given the current inadequate level of assurance around the identification of deliverable schemes.</li> <li>It is the Board's aspiration that a Target Operating Model can be constructed to focus delivery of services in the most optimum way for our patients and population, and is a critical part of the approach to the medium-term outlook. This will also align with the design assumptions set out in the Health Board's A Healthier Mid and West Wales strategy and Programme Business Case.</li> </ul>
<b>Next Steps</b>	<ul style="list-style-type: none"> <li>During Quarter 1, the development of the Target Operating Model in support of the draft three-year plan.</li> <li>Significant work will continue on developing key plans to deliver a clear core plan, focusing on recovery, which will allow the Health Board to get back on track with the financial roadmap, with a commitment to submit an approvable Financial Plan to WG.</li> <li>Management actions are urgently required to mitigate the YTD and end of year operational risk pressures.</li> </ul>

# Executive Summary


Summary of key financial targets					
<p>The Health Board's key targets are as follows:</p> <ul style="list-style-type: none"> <li>Revenue: to contain the overspend within the Health Board's planned deficit</li> <li>Savings: to deliver savings plans to enable the revenue budget to be achieved</li> <li>Capital: to contain expenditure within the agreed limit</li> <li>PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice</li> <li>Cash: While there is no prescribed limit for cash held at the end of the month, WG encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m.</li> </ul>					
Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	25.0	4.2	8.7	High*
Savings	£'m	29.4	4.9	1.9	High*
Capital	£'m	29.0	2.0	2.0	Low
Non-NHS PSPP	%	95.0	95.0	n/a	n/a
Period end cash	£'m	4.0	4.0	1.7	High**

\* The Health Board is forecasting a financial outturn position of £42.0m, which is £17.0m higher than the planned deficit of £25.0m. This is due to there being an inadequate level of assurance at this stage around the identification of a further £17.0m of savings schemes deliverable within the current financial year.


\*\* If WG do not fund the cash consequences of the revenue deficit, there is a significant risk to the period end cash position.

# Revenue Summary

## YTD variance by Directorate (against Plan)



## YTD actual by Directorate (COVID-19 only)




## Key drivers of YTD position

- **Savings non delivery £3.0m:** YTD value of savings undelivered by the organisation;
- **Unscheduled care £3.0m:** Continuation of site pressures where high levels of vacancies and activity are resulting in high variable pay expenditure across all four acute sites;
- **Facilities £0.9m:** Overspends are driven in core areas by the increasing cost of utilities and provisions and the loss of revenue in the Canteen and external vendors. COVID-19 expenditure relates to on-going expenditure in relation to enhanced cleaning standards across all HB estate and remedial works to HB estate;
- **Public Health £2.4m:** Primarily driven by costs associated with the Health Board's on-going response to COVID-19 in regards to TTP and Mass Vaccinations;
- **WG Programme Funding £(2.9)m:** YTD funding in respect of COVID-19 programme schemes totalling £2.9m have been included in the position;
- **WG Transitional Funding £(3.3)m** YTD funding has been assumed within the position to match transitional support costs in line with the Health Board's plan to exit, wherever possible, COVID-19 specific activities.

# Revenue Summary


## YTD variance by Subjective (against Plan)



## Key drivers of YTD position


- **Savings non delivery £3.0m:** YTD value of savings undelivered by the organisation;
- **Pay £4.3m:** Continued high levels of variable pay expenditure across various staff groups due to high levels of vacancies across the Health Board and on-going pressures in Unscheduled Care. Continued COVID-19 pay expenditure is primarily supporting the Health Board's response in respect of TTP, Mass Vaccination and enhanced cleaning standards;
- **Drugs £1.1m:** Oncology activity and price growth, increased gastroenterology activity and an increase in use of thrombolytics drugs due to additional patient risk assessments following a change in clinical guidelines.
- **Income £(1.0)m:** Primarily driven by the in-month recognition of Value Based Healthcare funding offset by consultancy charges in "Other".
- **WG Programme Funding £(2.9)m:** YTD funding in respect of COVID-19 programme schemes totalling £2.9m have been included in the position;
- **WG Transitional Funding £(3.3)m** YTD funding has been assumed within the position to match transitional support costs in line with the Health Board's plan to exit, wherever possible, COVID-19 specific activities.

## YTD actual by Subjective (COVID-19 only)







# Key Subjective Summary




# Key Subjective Summary

<div>CHC</div> <div><table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>4.2</td><td>4.2</td></tr><tr><td>P02-22</td><td>4.4</td><td>4.4</td></tr><tr><td>P03-22</td><td>4.8</td><td>4.8</td></tr><tr><td>P04-22</td><td>4.4</td><td>4.4</td></tr><tr><td>P05-22</td><td>4.2</td><td>4.2</td></tr><tr><td>P06-22</td><td>5.1</td><td>5.1</td></tr><tr><td>P07-22</td><td>4.5</td><td>4.5</td></tr><tr><td>P08-22</td><td>4.4</td><td>4.4</td></tr><tr><td>P09-22</td><td>4.5</td><td>4.5</td></tr><tr><td>P10-22</td><td>4.8</td><td>4.8</td></tr><tr><td>P11-22</td><td>4.2</td><td>4.2</td></tr><tr><td>P12-22</td><td>3.9</td><td>3.9</td></tr><tr><td>P01-23</td><td>4.2</td><td>4.2</td></tr><tr><td>P02-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P03-23</td><td>4.2</td><td>4.2</td></tr><tr><td>P04-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P05-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P06-23</td><td>4.2</td><td>4.2</td></tr><tr><td>P07-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P08-23</td><td>4.2</td><td>4.2</td></tr><tr><td>P09-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P10-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P11-23</td><td>3.9</td><td>3.9</td></tr><tr><td>P12-23</td><td>4.4</td><td>4.4</td></tr></table></div>	Period	Actual expenditure	Budgeted expenditure	P01-22	4.2	4.2	P02-22	4.4	4.4	P03-22	4.8	4.8	P04-22	4.4	4.4	P05-22	4.2	4.2	P06-22	5.1	5.1	P07-22	4.5	4.5	P08-22	4.4	4.4	P09-22	4.5	4.5	P10-22	4.8	4.8	P11-22	4.2	4.2	P12-22	3.9	3.9	P01-23	4.2	4.2	P02-23	4.4	4.4	P03-23	4.2	4.2	P04-23	4.4	4.4	P05-23	4.4	4.4	P06-23	4.2	4.2	P07-23	4.4	4.4	P08-23	4.2	4.2	P09-23	4.4	4.4	P10-23	4.4	4.4	P11-23	3.9	3.9	P12-23	4.4	4.4	<div>Continuing Health Care expenditure has increased by £0.1m in-month due to a small fluctutation in client numbers.</div>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	4.2	4.2																																																																										
P02-22	4.4	4.4																																																																										
P03-22	4.8	4.8																																																																										
P04-22	4.4	4.4																																																																										
P05-22	4.2	4.2																																																																										
P06-22	5.1	5.1																																																																										
P07-22	4.5	4.5																																																																										
P08-22	4.4	4.4																																																																										
P09-22	4.5	4.5																																																																										
P10-22	4.8	4.8																																																																										
P11-22	4.2	4.2																																																																										
P12-22	3.9	3.9																																																																										
P01-23	4.2	4.2																																																																										
P02-23	4.4	4.4																																																																										
P03-23	4.2	4.2																																																																										
P04-23	4.4	4.4																																																																										
P05-23	4.4	4.4																																																																										
P06-23	4.2	4.2																																																																										
P07-23	4.4	4.4																																																																										
P08-23	4.2	4.2																																																																										
P09-23	4.4	4.4																																																																										
P10-23	4.4	4.4																																																																										
P11-23	3.9	3.9																																																																										
P12-23	4.4	4.4																																																																										
<div>Secondary Care Drugs</div> <div><table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>4.0</td><td>3.7</td></tr><tr><td>P02-22</td><td>4.2</td><td>3.9</td></tr><tr><td>P03-22</td><td>3.7</td><td>3.8</td></tr><tr><td>P04-22</td><td>4.1</td><td>3.8</td></tr><tr><td>P05-22</td><td>3.9</td><td>3.8</td></tr><tr><td>P06-22</td><td>4.3</td><td>3.8</td></tr><tr><td>P07-22</td><td>4.2</td><td>4.0</td></tr><tr><td>P08-22</td><td>4.6</td><td>4.0</td></tr><tr><td>P09-22</td><td>4.5</td><td>4.0</td></tr><tr><td>P10-22</td><td>4.3</td><td>4.0</td></tr><tr><td>P11-22</td><td>4.0</td><td>4.0</td></tr><tr><td>P12-22</td><td>4.6</td><td>4.0</td></tr><tr><td>P01-23</td><td>4.0</td><td>3.9</td></tr><tr><td>P02-23</td><td>4.6</td><td>4.0</td></tr><tr><td>P03-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P04-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P05-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P06-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P07-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P08-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P09-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P10-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P11-23</td><td>3.8</td><td>3.8</td></tr><tr><td>P12-23</td><td>3.8</td><td>3.8</td></tr></table></div>	Period	Actual expenditure	Budgeted expenditure	P01-22	4.0	3.7	P02-22	4.2	3.9	P03-22	3.7	3.8	P04-22	4.1	3.8	P05-22	3.9	3.8	P06-22	4.3	3.8	P07-22	4.2	4.0	P08-22	4.6	4.0	P09-22	4.5	4.0	P10-22	4.3	4.0	P11-22	4.0	4.0	P12-22	4.6	4.0	P01-23	4.0	3.9	P02-23	4.6	4.0	P03-23	3.8	3.8	P04-23	3.8	3.8	P05-23	3.8	3.8	P06-23	3.8	3.8	P07-23	3.8	3.8	P08-23	3.8	3.8	P09-23	3.8	3.8	P10-23	3.8	3.8	P11-23	3.8	3.8	P12-23	3.8	3.8	<div>Secondary Care Drug expenditure has increased by £0.6m in-month. The primary drivers were increased gastroenterology activity and an increase in use of thrombolytics drugs due to additional patient risk assessments following a change in clinical guidelines.</div>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	4.0	3.7																																																																										
P02-22	4.2	3.9																																																																										
P03-22	3.7	3.8																																																																										
P04-22	4.1	3.8																																																																										
P05-22	3.9	3.8																																																																										
P06-22	4.3	3.8																																																																										
P07-22	4.2	4.0																																																																										
P08-22	4.6	4.0																																																																										
P09-22	4.5	4.0																																																																										
P10-22	4.3	4.0																																																																										
P11-22	4.0	4.0																																																																										
P12-22	4.6	4.0																																																																										
P01-23	4.0	3.9																																																																										
P02-23	4.6	4.0																																																																										
P03-23	3.8	3.8																																																																										
P04-23	3.8	3.8																																																																										
P05-23	3.8	3.8																																																																										
P06-23	3.8	3.8																																																																										
P07-23	3.8	3.8																																																																										
P08-23	3.8	3.8																																																																										
P09-23	3.8	3.8																																																																										
P10-23	3.8	3.8																																																																										
P11-23	3.8	3.8																																																																										
P12-23	3.8	3.8																																																																										

# Key Subjective Summary

<h3>Clinical Supplies and Services</h3> <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>2.6</td><td>2.7</td></tr><tr><td>P02-22</td><td>2.5</td><td>2.7</td></tr><tr><td>P03-22</td><td>2.8</td><td>2.8</td></tr><tr><td>P04-22</td><td>3.4</td><td>2.9</td></tr><tr><td>P05-22</td><td>3.4</td><td>2.9</td></tr><tr><td>P06-22</td><td>3.0</td><td>3.4</td></tr><tr><td>P07-22</td><td>2.7</td><td>2.9</td></tr><tr><td>P08-22</td><td>3.1</td><td>2.7</td></tr><tr><td>P09-22</td><td>3.8</td><td>2.9</td></tr><tr><td>P10-22</td><td>5.2</td><td>4.3</td></tr><tr><td>P11-22</td><td>3.5</td><td>3.4</td></tr><tr><td>P12-22</td><td>5.6</td><td>3.9</td></tr><tr><td>P01-23</td><td>3.0</td><td>2.8</td></tr><tr><td>P02-23</td><td>3.2</td><td>3.0</td></tr><tr><td>P03-23</td><td>2.7</td><td>2.6</td></tr><tr><td>P04-23</td><td>2.7</td><td>2.6</td></tr><tr><td>P05-23</td><td>2.7</td><td>2.6</td></tr><tr><td>P06-23</td><td>2.8</td><td>2.7</td></tr><tr><td>P07-23</td><td>2.8</td><td>2.7</td></tr><tr><td>P08-23</td><td>2.8</td><td>2.7</td></tr><tr><td>P09-23</td><td>2.8</td><td>2.7</td></tr><tr><td>P10-23</td><td>2.8</td><td>2.7</td></tr><tr><td>P11-23</td><td>2.8</td><td>2.7</td></tr><tr><td>P12-23</td><td>2.8</td><td>2.7</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	2.6	2.7	P02-22	2.5	2.7	P03-22	2.8	2.8	P04-22	3.4	2.9	P05-22	3.4	2.9	P06-22	3.0	3.4	P07-22	2.7	2.9	P08-22	3.1	2.7	P09-22	3.8	2.9	P10-22	5.2	4.3	P11-22	3.5	3.4	P12-22	5.6	3.9	P01-23	3.0	2.8	P02-23	3.2	3.0	P03-23	2.7	2.6	P04-23	2.7	2.6	P05-23	2.7	2.6	P06-23	2.8	2.7	P07-23	2.8	2.7	P08-23	2.8	2.7	P09-23	2.8	2.7	P10-23	2.8	2.7	P11-23	2.8	2.7	P12-23	2.8	2.7	<p>Actual expenditure increased by £0.2m in-month. The primary reason was an increase in M&amp;S purchases in endoscopy arising from an increased number of specialist procedures undertaken that required specific higher cost consumables</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	2.6	2.7																																																																										
P02-22	2.5	2.7																																																																										
P03-22	2.8	2.8																																																																										
P04-22	3.4	2.9																																																																										
P05-22	3.4	2.9																																																																										
P06-22	3.0	3.4																																																																										
P07-22	2.7	2.9																																																																										
P08-22	3.1	2.7																																																																										
P09-22	3.8	2.9																																																																										
P10-22	5.2	4.3																																																																										
P11-22	3.5	3.4																																																																										
P12-22	5.6	3.9																																																																										
P01-23	3.0	2.8																																																																										
P02-23	3.2	3.0																																																																										
P03-23	2.7	2.6																																																																										
P04-23	2.7	2.6																																																																										
P05-23	2.7	2.6																																																																										
P06-23	2.8	2.7																																																																										
P07-23	2.8	2.7																																																																										
P08-23	2.8	2.7																																																																										
P09-23	2.8	2.7																																																																										
P10-23	2.8	2.7																																																																										
P11-23	2.8	2.7																																																																										
P12-23	2.8	2.7																																																																										
<h3>Primary Care Prescribing</h3> <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>6.0</td><td>5.7</td></tr><tr><td>P02-22</td><td>5.7</td><td>5.4</td></tr><tr><td>P03-22</td><td>6.5</td><td>6.2</td></tr><tr><td>P04-22</td><td>6.5</td><td>6.1</td></tr><tr><td>P05-22</td><td>6.0</td><td>5.8</td></tr><tr><td>P06-22</td><td>6.4</td><td>6.3</td></tr><tr><td>P07-22</td><td>6.5</td><td>6.4</td></tr><tr><td>P08-22</td><td>6.4</td><td>6.4</td></tr><tr><td>P09-22</td><td>6.4</td><td>6.4</td></tr><tr><td>P10-22</td><td>5.8</td><td>5.8</td></tr><tr><td>P11-22</td><td>5.6</td><td>5.5</td></tr><tr><td>P12-22</td><td>6.0</td><td>6.5</td></tr><tr><td>P01-23</td><td>7.0</td><td>6.5</td></tr><tr><td>P02-23</td><td>6.8</td><td>6.6</td></tr><tr><td>P03-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P04-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P05-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P06-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P07-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P08-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P09-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P10-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P11-23</td><td>6.6</td><td>6.6</td></tr><tr><td>P12-23</td><td>6.6</td><td>6.6</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	6.0	5.7	P02-22	5.7	5.4	P03-22	6.5	6.2	P04-22	6.5	6.1	P05-22	6.0	5.8	P06-22	6.4	6.3	P07-22	6.5	6.4	P08-22	6.4	6.4	P09-22	6.4	6.4	P10-22	5.8	5.8	P11-22	5.6	5.5	P12-22	6.0	6.5	P01-23	7.0	6.5	P02-23	6.8	6.6	P03-23	6.6	6.6	P04-23	6.6	6.6	P05-23	6.6	6.6	P06-23	6.6	6.6	P07-23	6.6	6.6	P08-23	6.6	6.6	P09-23	6.6	6.6	P10-23	6.6	6.6	P11-23	6.6	6.6	P12-23	6.6	6.6	<p>Primary Care Prescribing costs have decreased by £0.2m in-month even though there was an additional prescribing day in the month. This is due to the one-off charge in Month 1 which was driven by an anticipated increase in the number of items prescribed in-month as Primary Care contractors begin moving patients into a 56 day prescribing interval.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	6.0	5.7																																																																										
P02-22	5.7	5.4																																																																										
P03-22	6.5	6.2																																																																										
P04-22	6.5	6.1																																																																										
P05-22	6.0	5.8																																																																										
P06-22	6.4	6.3																																																																										
P07-22	6.5	6.4																																																																										
P08-22	6.4	6.4																																																																										
P09-22	6.4	6.4																																																																										
P10-22	5.8	5.8																																																																										
P11-22	5.6	5.5																																																																										
P12-22	6.0	6.5																																																																										
P01-23	7.0	6.5																																																																										
P02-23	6.8	6.6																																																																										
P03-23	6.6	6.6																																																																										
P04-23	6.6	6.6																																																																										
P05-23	6.6	6.6																																																																										
P06-23	6.6	6.6																																																																										
P07-23	6.6	6.6																																																																										
P08-23	6.6	6.6																																																																										
P09-23	6.6	6.6																																																																										
P10-23	6.6	6.6																																																																										
P11-23	6.6	6.6																																																																										
P12-23	6.6	6.6																																																																										

# Financial Projection



## Key Assumptions

- The direct impact of COVID-19, including programme expenditure (in respect of mass vaccination programmes, Testing, Tracing, and PPE) is modelled up to a twelve-month scenario within the current forecast; this is under review ahead of Month 3 to assess the impact of the WG de-escalation of COVID-19 measures guidance received in May 2022.
- All assumed WG COVID-19 and Exceptional Costs (Energy, Health and Social Care Levy and Real Living Wage commissioned services) funding is based on the current forecast costs on a match-basis.

## Assurance

- Executive led Use of Resources Group which scrutinises business cases, opportunities and financial governance.
- Performance to be monitored monthly through robust Directorate Use of Resources meetings.


## Concerns

- There is a significant risk that the underlying deficit of £53.9m will continue if recurrent savings schemes of £28.9m are not identified in-year. Whilst this is an improvement from the 2021/22 position of £68.9m, this presents a challenge to be addressed as part of the revised Financial Plan based on our Target Operating Model.

## Next Steps

- Continue to engage with partner organisations to develop plans to address the issues within the Primary Care and Social Care sectors.
- During Quarter 1, the development of the Target Operating Model in support of the draft three-year plan.
- Significant work will continue on developing key plans to deliver a clear core plan, focusing on recovery, which will allow the Health Board to get back on track with the financial roadmap, with a commitment to submit an approvable Financial Plan to WG.

# Savings schemes



## Appendix 1: Monitoring return tables

Table	Commentary																				
<b>Board Governance Arrangements</b>	<p>In the absence of the Director of Finance, the Deputy Director of Finance, Mr Andrew Spratt, is authorised to approve and sign this report. In the absence of the Chief Executive, the Director of Operations, Mr Andrew Carruthers, is authorised to approve and sign this report.</p> <p>This body of this report (including Appendix 1 and 2) will be presented to the next Sustainable Resources Committee meeting, to be held on 28<sup>th</sup> June 2022. All Tables will be appended.</p>																				
<b>Table A: Movement</b>	<p>Opening section of Table A reflects the latest version of the Financial Plan, with Line 1 (Underlying b/f position) being that submitted in the Month 12 2021/22 MMR Tables. The COVID-19 forecast modelling is based on an up to 12-month scenario, whereby it is assumed that COVID-19 will continue to have a transitional financial impact over the full year, however the response required is now significantly reduced from the prior year. Following the review led by Infection Prevention and Control Group, further work is on-going to challenge the timescales over which additional costs are forecast to continue in conjunction with understanding the decisions that could be taken to reduce or cease the financial impact of the Health Board's operational response. This review will now also assess the impact of the WG de-escalation of COVID-19 measures guidance received in May 2022, with the expectation that work will be concluded for reporting in the Month 3 submission. All COVID-19 expenditure has been assumed to be non-recurrent.</p> <p>The Non-COVID-19 WG funding (Line 4) of £64.644m is taken from the MDS submission; £54.0m is classified as recurrent and £10.7m (in respect of Exceptional Energy) is classified as non-recurrent. A breakdown is provided below, indicating which funding items are confirmed and which have been assumed as this stage in line with the WG guidance provided as part of the financial planning cycle:</p> <table> <tr> <th>Item</th><th>£'m</th></tr> <tr> <td>Core Uplift – confirmed</td><td>18.969</td></tr> <tr> <td>Planned and Unscheduled Care Sustainability – confirmed</td><td>21.742</td></tr> <tr> <td>Mental Health Core Uplift – confirmed</td><td>2.450</td></tr> <tr> <td>Value Based Recovery – confirmed</td><td>1.897</td></tr> <tr> <td>Urgent and Emergency Care – confirmed</td><td>2.800</td></tr> <tr> <td>Employer's National Insurance (Exceptional) – assumed</td><td>3.040</td></tr> <tr> <td>Real Living Wage for Commissioned Services (Exceptional) – assumed</td><td>3.086</td></tr> <tr> <td>Energy costs (Exceptional) – assumed</td><td>10.660</td></tr> <tr> <td><b>Total</b></td><td><b>64.644</b></td></tr> </table>	Item	£'m	Core Uplift – confirmed	18.969	Planned and Unscheduled Care Sustainability – confirmed	21.742	Mental Health Core Uplift – confirmed	2.450	Value Based Recovery – confirmed	1.897	Urgent and Emergency Care – confirmed	2.800	Employer's National Insurance (Exceptional) – assumed	3.040	Real Living Wage for Commissioned Services (Exceptional) – assumed	3.086	Energy costs (Exceptional) – assumed	10.660	<b>Total</b>	<b>64.644</b>
Item	£'m																				
Core Uplift – confirmed	18.969																				
Planned and Unscheduled Care Sustainability – confirmed	21.742																				
Mental Health Core Uplift – confirmed	2.450																				
Value Based Recovery – confirmed	1.897																				
Urgent and Emergency Care – confirmed	2.800																				
Employer's National Insurance (Exceptional) – assumed	3.040																				
Real Living Wage for Commissioned Services (Exceptional) – assumed	3.086																				
Energy costs (Exceptional) – assumed	10.660																				
<b>Total</b>	<b>64.644</b>																				

## Appendix 1: Monitoring return tables

Table	Commentary												
	Planning assumptions to be finalised of £17.0m relates to an inadequate level of assurance around the delivery of a further £17.0m of savings schemes within the current financial year as at Month 2.												
<b>Table A1: Underlying Position</b>	<p>Table A1 has been completed based on the Financial Plan submission Tables for 2022/23, adjusted as follows:</p> <table> <tr> <th>Item</th><th>£'m</th></tr> <tr> <td>MDS Forecast FYE outturn (opening pressure less all savings)</td><td>(34.0)</td></tr> <tr> <td>FYE "Red" Pipeline included in MDS not included in Table A as not "Finalised"/non-recurrent schemes</td><td>(29.0)</td></tr> <tr> <td>Correction to Green/Amber schemes FYE only</td><td>0.2</td></tr> <tr> <td>Assumption correction from non-recurrent to recurrent re WG funding in respect of Employer's National Insurance (Exceptional) £3.0m, Real Living Wage (Exceptional) £3.1m and Urgent and Emergency Care £2.8m</td><td>8.9</td></tr> <tr> <td><b>Table A Opening IMTP</b></td><td><b>(53.9)</b></td></tr> </table> <p>The net improvement in the underlying deficit from 2021/22 of £68.9m to the current assessment for 2022/23 of £53.9m is due to the investment of the Planned and Unscheduled Care Sustainability allocation recurrently against new Recovery (primarily demountable theatre capacity and Ophthalmology activity) and Sustainability schemes (Integrated Localities and Urgent and Emergency Care), investment in statutory changes in Nurse Staffing acuity levels and the levelling up of resourcing requirements within Unscheduled Care, predominately recognising our variable pay run rates and Emergency Department rostering. Following discussions with WG and FDU colleagues we understand that we will need to demonstrate the linkages of investments to elective activity increases; further work is on-going to provide sufficient evidence and assurance.</p>	Item	£'m	MDS Forecast FYE outturn (opening pressure less all savings)	(34.0)	FYE "Red" Pipeline included in MDS not included in Table A as not "Finalised"/non-recurrent schemes	(29.0)	Correction to Green/Amber schemes FYE only	0.2	Assumption correction from non-recurrent to recurrent re WG funding in respect of Employer's National Insurance (Exceptional) £3.0m, Real Living Wage (Exceptional) £3.1m and Urgent and Emergency Care £2.8m	8.9	<b>Table A Opening IMTP</b>	<b>(53.9)</b>
Item	£'m												
MDS Forecast FYE outturn (opening pressure less all savings)	(34.0)												
FYE "Red" Pipeline included in MDS not included in Table A as not "Finalised"/non-recurrent schemes	(29.0)												
Correction to Green/Amber schemes FYE only	0.2												
Assumption correction from non-recurrent to recurrent re WG funding in respect of Employer's National Insurance (Exceptional) £3.0m, Real Living Wage (Exceptional) £3.1m and Urgent and Emergency Care £2.8m	8.9												
<b>Table A Opening IMTP</b>	<b>(53.9)</b>												
<b>Table A2: Risks and Opportunities</b>	<p><b>Risks</b></p> <p>The Amber savings schemes are assumed to have a delivery risk of 20% across all Amber schemes at Month 2 given that the majority are expected to deliver in the latter part of the year and that a number will depend on the success rate of recruitment plans. We are also managing a further risk to the updated forecast in relation to the operational pressures experienced in Months 1 and 2; as a minimum there is a need to recover the £1.5m operational variation during the remainder of the year, and there is the potential for a continuation of a number of these pressures without full mitigation.</p> <p>As there has been no confirmation of the availability of WG COVID-19 Transitional funding or Exceptional Costs funding, there is a risk to the financial position should that funding not be available to the Health Board.</p>												

## Appendix 1: Monitoring return tables

Table	Commentary
	<p><b>Opportunities</b></p> <p>There are no quantifiable opportunities to report in the Month 2 submission, however the Target Operating Model is listed as it is hoped that this work will identify opportunities.</p>
<b>Table B: Monthly position</b>	<p>The forecast has been calculated using Directorate projections of both the “non-COVID-19” and COVID-19 profiled positions as a basis. Finance Business Partners forecast against income and expenditure categories aligned to the subjective hierarchy; this has then been mapped into SCNE categories for the purposes of Table B. All Reserves have been allocated to Directorates to manage as part of the financial planning cycle.</p> <p>Section B has been completed based on the above consolidated forecasts. The correlation between this and the Directorate analysis of the underlying deficit in Table A1 will be reviewed once the revised Plan has been submitted after Q1, when further clarity is expected regarding the drivers of the underlying position.</p> <p>The Health Board’s in-month result was £0.8m higher compared to the Month 1 forecast. A high level analysis of key movements is summarised below. Please note that the narrative relates to the Non-COVID movements only. Pay commentary is included within section B2 and COVID-19 commentary is included within the narrative for Section B3.</p> <ul style="list-style-type: none"> <li>• <b>Revenue Resource Limit £1.2m:</b> Re-phasing of the RRL.</li> <li>• <b>Welsh Government income (Non RRL) £(0.6)m:</b> YTD correction of a mis-classification within the Month 1 reported position.</li> <li>• <b>Primary Care contractor £0.6m:</b> Recognition of enhanced service payments earlier than previous forecast.</li> <li>• <b>Secondary Care Drugs £0.4m:</b> The primary drivers were increased gastroenterology activity and an increase in use of thrombolytics drugs due to additional patient risk assessments following a change in clinical guidelines, neither of which were included within the forecast.</li> </ul> <p>The Health Board’s EoY forecast is unchanged compared to the Month 1 forecast, however there were deviations between expenditure categories. Please note that the narrative relates to the Non-COVID movements only. Pay commentary is included within section B2 and COVID-19 commentary is included within the narrative for Section B3. The key drivers are summarised below:</p> <ul style="list-style-type: none"> <li>• <b>Welsh Government income (Non RRL) £3.3m:</b> Correction of a mis-classification within the Month 1 reported position which had been factored into the EoY forecast in error.</li> <li>• <b>Other Income (£1.8m):</b> Linked to the above correction of the mis-classification error.</li> </ul>



## Appendix 1: Monitoring return tables

Table	Commentary																																												
	<ul style="list-style-type: none"><li>• <b>Provider Services – Non-Pay £(1.7)m:</b> A review of Digital SLAs and recognition of British Gas rebates in excess of expectations (relating to 3 financial years);</li><li>• <b>Healthcare Services Provided by Other NHS Bodies £(0.9)m:</b> Revised contractual assumptions following an in-month review.</li><li>• <b>Continuing Care and FNC £(0.5)m:</b> The mix of packages of care has led to an improvement in the forecast.</li></ul>																																												
<b>Table B2: Pay and agency</b>	<p>See key subjective section above.</p> <p><b><u>Section A</u></b></p> <p><b><u>Movement against in-month Pay forecast</u></b> The Health Board’s in-month result was £0.2m higher than the Month 1 forecast.</p> <p><b><u>Movement against EoY Pay forecast</u></b></p> <table><tr><th>Category</th><th>Movement to forecast</th><th>COVID-19</th><th>Non COVID</th></tr><tr><td>Administrative, Clerical &amp; Board</td><td>278</td><td>368</td><td>(90)</td></tr><tr><td>Medical &amp; Dental</td><td>212</td><td>(292)</td><td>504</td></tr><tr><td>Nursing &amp; Midwifery Registered</td><td>(219)</td><td>616</td><td>(835)</td></tr><tr><td>Prof Scientific &amp; Technical</td><td>20</td><td>(24)</td><td>44</td></tr><tr><td>Additional Clinical Services</td><td>64</td><td>497</td><td>(433)</td></tr><tr><td>Allied Health Professionals</td><td>116</td><td>48</td><td>68</td></tr><tr><td>Healthcare Scientists</td><td>(48)</td><td>(5)</td><td>(43)</td></tr><tr><td>Estates &amp; Ancillary</td><td>(106)</td><td>(236)</td><td>130</td></tr><tr><td>Students</td><td>(30)</td><td>0</td><td>(30)</td></tr><tr><td><b>Total movement</b></td><td><b>286</b></td><td><b>972</b></td><td><b>(686)</b></td></tr></table> <p>The key driver of deviation between COVID-19 and Non-COVID-19 relates to the correction of the treatment of the dedicated COVID-19 WGH ward in Month 2; the other deviations within Non-COVID-19 were immaterial. Please see Section B3 for COVID-19 narrative.</p>	Category	Movement to forecast	COVID-19	Non COVID	Administrative, Clerical & Board	278	368	(90)	Medical & Dental	212	(292)	504	Nursing & Midwifery Registered	(219)	616	(835)	Prof Scientific & Technical	20	(24)	44	Additional Clinical Services	64	497	(433)	Allied Health Professionals	116	48	68	Healthcare Scientists	(48)	(5)	(43)	Estates & Ancillary	(106)	(236)	130	Students	(30)	0	(30)	<b>Total movement</b>	<b>286</b>	<b>972</b>	<b>(686)</b>
Category	Movement to forecast	COVID-19	Non COVID																																										
Administrative, Clerical & Board	278	368	(90)																																										
Medical & Dental	212	(292)	504																																										
Nursing & Midwifery Registered	(219)	616	(835)																																										
Prof Scientific & Technical	20	(24)	44																																										
Additional Clinical Services	64	497	(433)																																										
Allied Health Professionals	116	48	68																																										
Healthcare Scientists	(48)	(5)	(43)																																										
Estates & Ancillary	(106)	(236)	130																																										
Students	(30)	0	(30)																																										
<b>Total movement</b>	<b>286</b>	<b>972</b>	<b>(686)</b>																																										

## Appendix 1: Monitoring return tables

Table	Commentary
<b>Table B3: COVID-19</b>	<p><b><u>Section A</u></b></p> <p>The Reporting and Forecasting Principles Paper developed internally in 2020/21, based on the WG guidance, has been applied consistently to identify and quantify the additionality of costs incurred in response to the COVID-19 pandemic. This Paper outlines the process henceforth in terms of the decision-making framework for Use of Resources Group and the flow of decisions/information from that forum to inform financial forecasting. Exit plans for all COVID-19 transitional schemes are being reviewed by the operational teams and have already indicated a reduction to the original plan; from £27.8m to £16.4m in the latest (Month 2) forecast, a reduction of £11.4m, which has significantly reduced the risk we presented previously.</p> <p>The key operational drivers of the “Other” classification are as follows:</p> <ul style="list-style-type: none"> <li>• Housekeeping activities (in addition to Enhanced Cleaning Standards) for additional waste, laundry, front of house duties, cleaning and maintenance (Porters, Domestic staff, Maintenance staff);</li> <li>• Designated COVID-19 Acute bed capacity for Red pathways, increased acuity in Critical Care and ward remodels (BGH Y Banwy Annex 12 beds (3 RN, 6 HCSW), GGH Padarn ward 16 beds, PPH ward remodel and Puffin ward WGH);</li> <li>• Pathway duplication, leading to additional staffing requirements (variable pay and fixed term resource for Red pathways on Emergency and Women &amp; Children streaming, General Surgery Medics supporting pathways in PPH);</li> <li>• Community bed capacity for step down facilities (Amman Valley, Tregaron and Llys y Bryn);</li> <li>• PPE (programme expenditure);</li> <li>• Primary Care Prescribing (significant price increase in April 2020, All-Wales approach deemed due to COVID-19);</li> <li>• Drugs: acute changes to treatment regimes (Cancer patients switched from intravenous to sub cutaneous, PPH switched from hospital to home setting);</li> <li>• Long COVID-19 Service;</li> <li>• Investigation and learning from Nosocomial Cases;</li> <li>• Additional WAST vehicle to support discharge;</li> <li>• RSV Paediatric Service.</li> </ul> <p>Loss of Dental (GDS) income has been excluded following the confirmation of a non-recurrent anticipated allocation in respect of a reduction to the dental patient charge revenue target for 2022/23 so that they better match likely charge income in 2022-23. The method of calculation for this will be reviewed with the assistance of FDU colleagues as we understand that other organisations are reporting loss of dental income despite the allocation and will ensure that we are applying a consistent methodology across Wales from the Month 3 submission onwards.</p> <p>The actual Month 2 costs were £0.5m higher than forecast in Month 1, primarily due to the following reasons:</p> <ul style="list-style-type: none"> <li>• <b>Tracing – Joint Financing £0.1m:</b> Higher than anticipated Local Authority expenditure levels;</li> </ul>

## Appendix 1: Monitoring return tables

Table	Commentary
	<ul style="list-style-type: none"> <li>• <b>Mass vaccinations – Primary Care Contractor £0.1m:</b> Claims received in Month 2 in respect of activity delivered in 2021/22 from GMS contractors in line with enhanced services claim window;</li> <li>• <b>Other – Provider Non Pay - PPE £0.1m:</b> Higher than anticipated use of PPE during the month;</li> <li>• <b>Other – Healthcare Services Provided by Other NHS Bodies £0.2m:</b> Correction of an omission in Month 1 (therefore 2 months of charges in Month 2) in respect of an additional WAST vehicle in support of discharge.</li> </ul> <p>The increase of £1.2m in the EoY forecast from Month 1 to 2 primarily relates to an additional COVID-19 dedicated ward in WGH (£1.1m) which was not captured in Month 1 COVID-19 reporting.</p> <p><b><u>Section B</u></b></p> <p>The Planned funding on line is based on forecasts as at Month 1; the £1.2m deviation to Plan in Month 2 is primarily due to the addition of a COVID-19 dedicated ward in WGH.</p> <p><b><u>Annual Leave Provision</u></b></p> <p>The b/f provision from 2021/22 was £12,781,765 and the 'sell back' payment processed in the June 2022 payroll run is £815,143, leaving a current provision of £11,966,622. We understand that payroll have received a number of amendments to applications to carry over or sell leave from the 2021/22 year despite being after the agreed deadline and errors have been identified in some submissions which has meant that not all submissions could be processed and have been returned to line managers for clarification. It is expected that the majority of errors will be resolved ahead of July's payruns, however there is a risk that some may fall into the August payrun. Therefore, the above provision will be amended for the revised 'sell back' value with the latest information from payroll.</p>
<b>Table C3: Savings Tracker</b>	<p>Since submission of the MDS and financial plan further Green/Amber savings schemes have been identified, however this has largely been on a non-recurrent basis. A number of schemes have been split across 2 lines with the earlier delivery considered to be Green and the forecast delivery later in the year considered to be Amber, with a 'date expected to go Green' of 1<sup>st</sup> July 2022; this is linked to the development of the Target Operating Model in aligning priorities around this approach and the areas of opportunity identified. It is the Board's aspiration to deliver this by the end of the first quarter of this financial year to address the challenges which will allow us to get back on track with our financial roadmap and provide further assurance around either the conversion of Amber schemes to Green or the delivery of alternative opportunities operationally.</p> <p>A key factor in worsening the current financial outturn projection is the risk surrounding delivery assurance over the opportunities that have been incorporated into the plan. Having the clarity of the opportunities has enabled the team to buy into the areas that need to be influenced and changed, but we are yet to agree and have sight of detailed plans that illustrate a clear route to</p>


## Appendix 1: Monitoring return tables

Table	Commentary
	delivery through our planning framework. This is our key priority and linked to the Target Operating Model that will shape our revised Financial Plan submission. Whilst discussions have been extremely positive in aligning priorities around this approach and the areas of opportunity, we have come to recognise that the impact of delivery for the 2022/23 financial year is only going to be very modest, given the complexities involved within the fragility of the system pressures.
<b>Table D: Welsh NHS Assumptions</b>	The submission will be revised in future months once all LTA agreements are agreed and signed.
<b>Table E: Resource limits</b>	<p>The Health Board's planning assumptions are that it will receive resource allocation income of £1,020.105m from Welsh Government in the 2022/23 financial year. This comprises of notified allocation of £954.882m and allocations pending of £65.223m.</p> <p>Pending allocations in relation to specific programme COVID-19 costs (Testing, Tracing, COVID-19 mass vaccination programme, and PPE) are considered to be confirmed on a match-funded basis. It is currently assumed, following initial guidance from WG during the financial planning cycle, that match-funding will also be available for the transitional costs of COVID-19, which also includes Enhanced Cleaning Standards. Specific funding confirmation letters have been received for fixed sums in respect of the Long COVID-19 Service and Nosocomial COVID-19, however we are only anticipating the amount of funding currently forecast to be needed to match costs. All COVID-19 funding values are based on the Month 2 Directorate forecasts.</p> <p>The assumed transitional funding has been classified by theme based on the additional 'Other COVID-19' template submitted as part of the supplementary MMR templates.</p>
<b>Table F: Statement of Financial Position</b>	This table is not required in Month 2.

Appendix 1: Monitoring return tables

Table	Commentary
Table G: Cashflow	<div><div><div>10,000</div><div>5,000</div><div>0</div><div>5,000</div><div>10,000</div><div>15,000</div><div>20,000</div><div>25,000</div><div>30,000</div></div><div>Receivables and Cash</div><div>Payables</div><div><div>Over 90 days</div><div>60-90 days</div><div>30-60 days</div><div>Under 30 days</div><div>Cash</div></div><div>May-21Jun-21Jul-21Aug-21Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22</div></div> <div><ul style="list-style-type: none"><li>Balances owed to the Health Board from income collected from sources other than Welsh Government are £5m.</li><li>With regards to the Health Board's Aged Payables position, at the end of May 2022 £18.5m was owed to suppliers, of which £11.1m are less than 30 days old.</li></ul></div>

## Appendix 1: Monitoring return tables

Table	Commentary																																																								
	<div><table><caption>Estimated Data from Chart</caption><thead><tr><th>Month</th><th>Draw down (£'m)</th><th>WG max cash balance (£'m)</th><th>Cash balance (£'m)</th></tr></thead><tbody><tr><td>May-21</td><td>90</td><td>4.5</td><td>1.8</td></tr><tr><td>Jun-21</td><td>95</td><td>4.8</td><td>1.5</td></tr><tr><td>Jul-21</td><td>92</td><td>4.6</td><td>2.5</td></tr><tr><td>Aug-21</td><td>85</td><td>4.3</td><td>3.5</td></tr><tr><td>Sep-21</td><td>78</td><td>4.0</td><td>3.2</td></tr><tr><td>Oct-21</td><td>85</td><td>4.3</td><td>2.5</td></tr><tr><td>Nov-21</td><td>90</td><td>4.6</td><td>1.8</td></tr><tr><td>Dec-21</td><td>93</td><td>4.8</td><td>1.2</td></tr><tr><td>Jan-22</td><td>82</td><td>4.5</td><td>2.0</td></tr><tr><td>Feb-22</td><td>102</td><td>5.1</td><td>7.5</td></tr><tr><td>Mar-22</td><td>112</td><td>5.5</td><td>1.5</td></tr><tr><td>Apr-22</td><td>108</td><td>5.2</td><td>-1.5</td></tr><tr><td>May-22</td><td>92</td><td>4.8</td><td>1.7</td></tr></tbody></table></div> <ul style="list-style-type: none"><li>• The closing balance is £1.7m.</li><li>• The Health Board has an approved cash limit of £983.8m split between revenue £954.9m and capital £28.9m.</li><li>• Cumulative cash drawn down to Month 2 is £199.6m. Emergency cash of £9m was received in the month, this was mainly due to higher than anticipated creditor payments.</li><li>• The bank balance in month 1 was overdrawn to the value of £1.8m. This was due to a request for emergency cash of £5m not processed by WG. WG have acknowledged that it was an oversight on their part and have confirmed that there is no penalty for going overdrawn.</li><li>• The full year deficit reflects the forecast outturn of the financial position.</li></ul>	Month	Draw down (£'m)	WG max cash balance (£'m)	Cash balance (£'m)	May-21	90	4.5	1.8	Jun-21	95	4.8	1.5	Jul-21	92	4.6	2.5	Aug-21	85	4.3	3.5	Sep-21	78	4.0	3.2	Oct-21	85	4.3	2.5	Nov-21	90	4.6	1.8	Dec-21	93	4.8	1.2	Jan-22	82	4.5	2.0	Feb-22	102	5.1	7.5	Mar-22	112	5.5	1.5	Apr-22	108	5.2	-1.5	May-22	92	4.8	1.7
Month	Draw down (£'m)	WG max cash balance (£'m)	Cash balance (£'m)																																																						
May-21	90	4.5	1.8																																																						
Jun-21	95	4.8	1.5																																																						
Jul-21	92	4.6	2.5																																																						
Aug-21	85	4.3	3.5																																																						
Sep-21	78	4.0	3.2																																																						
Oct-21	85	4.3	2.5																																																						
Nov-21	90	4.6	1.8																																																						
Dec-21	93	4.8	1.2																																																						
Jan-22	82	4.5	2.0																																																						
Feb-22	102	5.1	7.5																																																						
Mar-22	112	5.5	1.5																																																						
Apr-22	108	5.2	-1.5																																																						
May-22	92	4.8	1.7																																																						
Table H: PSPP	No update required for Month 2.																																																								
Table I: Capital RLM	As identified in WG dashboard additional discretionary capital contribution is required for the Womens & Childrens scheme.  Provision has been made for the deposit on purchase of land for the Cross Hands Primary Care Scheme.																																																								

## Appendix 1: Monitoring return tables

Table	Commentary
<b>Table J: Capital In Year Schemes</b>	It is not anticipated at this stage that there will be any slippages in 2022/23 capital allocations, therefore all schemes have been assigned a low risk rating.
<b>Table K: Capital disposals</b>	No disposals are currently expected other than equipment disposals which will be reported when they occur.
<b>Table M: Aged debtors</b>	As of the 31 <sup>st</sup> of May there are no invoices outstanding over 11 weeks
<b>Table N: GMS</b>	This table is not required in Month 2.
<b>Table O: Dental</b>	This table is not required in Month 2.

## Appendix 2: Monitoring return reply letter

Reply Letter Action – Month 1 2022/23	Health Board Response
<p>I am also concerned that the Month 1 deficit position is c. £0.950m higher than expected and that a corresponding risk of £6.000m is being reported. You will be acutely aware of the need to rapidly cease and reverse this run rate and recover the overspend; I note that the recovery of the Month 1 pressure is phased over the remaining 11 months. Please ensure a comprehensive update is provided at Month 2 describing the urgent actions being taken. <b>(Action Point 1.1)</b></p>	<p>The Month 2 position is also of concern, and unidentified savings have been assumed to mitigate the YTD position. This poses an increased risk to the EoY forecast, which has been reflected in Table A2. A full review will be undertaken ahead of the Month 3 submission.</p>
<p>Having reviewed the WG funding line it would appear that your Plan is assigning c. £7.700m of the now recurrent Recovery Funding, to the improvement of your b/f underlying position. As discussed in the 'Deep Dive' session, further clarity was provided by Steve Elliot on the expectation usage of this funding, and you were advised to urgently discuss this further with performance colleagues. I will look to your Month 2 submission for a further update. <b>(Action Point 1.2)</b></p>	<p>See Section A1.</p>
<p>I refer to the 21/22 'In Year Expenditure Cost Reduction Due To Covid-19' totalling £4.617m and whilst I acknowledge that the WHSSC and Dental items would not be available this year, please could you clarify the status of the balance of c £2.6m predominately described as non pay releases. I.E., are these now being incurred in the original pre-covid areas or has an element been reflected in the 22/23 saving plans. <b>(Action Point 1.3)</b></p>	<p>The £1.5m of reduced non-pay costs from reduced elective activity and other cost reductions were largely delivered in the first 4/5 months of 2021/22, with activity levels increasing as the year progressed and continuing into this financial year.</p>
<p>Although you will receive feedback from the FDU, I note that movement in annual forecast energy costs is £7.192m (£15.400m less £8.208m); however the incremental reported amount and anticipated funding value is lower at £6.919m. Please review and clarify your latest funding assumption. The FDU are to confirm shortly a consistent methodology for the basis of the 'incremental charge', to use going forward. At Month 2, please confirm the basis of the 21/22 baseline (e.g. final based on Jan or March plus 2%), the basis of the latest forecast (B Gas &amp; or Local) and reflect the correct value in the 'incremental' cell. If increased costs are being fully or partly managed internally, please also ensure this is highlighted and explained within your narrative. <b>(Action Point 1.4)</b></p>	<p>The Month 1 total energy forecast included 'normal' inflation in addition to the exceptional price increases (which was built into our financial plan and funded through our core allocation uplifts). We have adopted the methodology provided by FDU for the Month 2 submission, which should resolve this issue.</p>
<p>Whilst I acknowledge the separate anticipated income item for the 21/22 Bands 1 &amp; 2 uplift (which will be issued in due course); I note that you are anticipating 'RLW Health' funding totalling £0.842m via Table E for 22/23. As you are aware, this element will be determined via the pay negotiation process; therefore, please do not use the Pay line on the FDU template and remove any associated 22/23 funding assumptions from Table E, until this is concluded. <b>(Action Point 1.5)</b></p>	<p>The income assumption for 'RLW Health' has been removed in the Month 2 submission.</p>
<p>Although you will also receive feedback from the FDU on the costs reported in the 'Other Covid-19' Template, I note that the forecast "Prescribing costs directly related to Covid</p>	<p>We have discussed the treatment of costs included within the Prescribing theme with FDU colleagues</p>



## Appendix 2: Monitoring return reply letter

Reply Letter Action – Month 1 2022/23	Health Board Response
symptoms” of £6.742m represents the highest value in Wales (and in most cases, is significantly higher than other HBs). The supporting narrative indicates that you are assigning the majority (if not all) of primary care prescribing price increases since April 20 to Covid-19. Please work with the FDU to ensure your costs for this area align to the criteria, before the Month 2 submission. <b>(Action Point 1.6)</b>	and are undertaking an internal review of the Primary Care Prescribing element (£4.4m) ahead of the Month 3 submission.
The costs of the Extended Flu Programme (for all applicable age groups) should be included in your Table B3 in 2022/23 and you can anticipate Covid funding (the allocations will be confirmed in due course and therefore this is not anticipated at risk). During this year, should any funding for policy areas be confirmed as recurrent from 23/24, please continue to record them as non-recurrent this year; when issued recurrently, they become Operational in 23/24. Please reflect the Extended Flu Programme in our Month 2 submission. <b>(Action Point 1.7)</b>	Finance leads are aware that costs should be included in the COVID-19 forecast, and have been engaging with service leads to assess the financial impact, however conclusions have not been reached in time for inclusion in the Month 2 submission; this will be corrected in Month 3.
The identified plan of c. £12.400m is currently projected to deliver a relatively minor FYE recurring savings value of £0.467m. This is of significant concern and highlights the non-recurring transactional nature of the plans rather than recurring transformational. Your ‘Target Operating Model’ is referenced in the supporting narrative as likely to have a ‘very modest’ impact this year. I also note that c 45% of the identified savings are currently classified Amber and you are reminded of the 3-month timeframe to progress these to a Green status, which provides assurance of your forecast outturn. I look forward to receiving a further update on your savings plans next month and please review the ‘Go Green’ dates recorded in the Tracker, as currently these are reported as ‘2023’. <b>(Action Point 1.8)</b>	A full update will be provided in the Month 3 submission. The ‘Go Green’ dates within Table C3 have been updated.
I refer again to the Month 1 operational pressure (your AO letter confirms this mainly relates to unscheduled care pressures) of £0.946m. This is currently being reported on line 21 which is meant for RRL/Other Income phasing issues. It would appear that the appropriate line to record this line 26, where you can reflect an appropriate description. Please consider this for Month 2. <b>(Action Point 1.9)</b>	Table A has been updated to reflect this.
As you are forecasting that the b/f underlying position will improve by £14.989m as a result of recurring funding, please ensure the corresponding positive values are reported in the ‘Recurring Allocations / income’ column of Table A1. It is acknowledged that the value quoted here, may change depending on the outcome of the usage issue of your Recovery Funding. <b>(Action Point 1.10)</b>	Table A1 has been amended to reflect this for the Month 2 submission.
All organisations are being requested to provide the following information on the Annual Leave Accrual within the Month 2 narrative <b>(Action Point 1.11)</b> : 1) b/f Opening Annual Leave Accrual value 2) remaining Annual Leave Accrual balance after ‘Sell Back’	See section B3. We will provide a breakdown of the payment by staff group in the Month 3 submission within section B2.

## Appendix 2: Monitoring return reply letter

Reply Letter Action – Month 1 2022/23	Health Board Response																		
Please treat the 'Investigation and learning from Nosocomial Cases' anticipated funding as a Covid-19 allocation in your next return, with the corresponding spend also to be included within Section A6 'Other' of Table B3. <b>(Action Point 1.12)</b>	This has been included in theme D5 within Table E.																		
In addition, please also reflect your '22/23 loss of dental income' funding item as a Covid-19 allocation, with the corresponding spend being reported on Line 158 (Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS Income) of Table B3. <b>(Action Point 1.13)</b>	Please see Section B3.																		
<p>I acknowledge that you have already assisted us via the way you have set out the Covid 'other' funding in Table E. For completeness, the details below reflect the request being made of other HBs which I would be grateful if you could also follow. In order to better align non-programme Covid-19 funding assumptions against the 'Other' analysis reported within the FDU template; all organisations are being requested to split their income assumptions across the below categories within the Covid-19 section of Table E/Table E1. The lines below will be linked to consolidation tables in our internal systems; therefore, please do not use these lines for any other income items. To reduce error, we suggest you add the narrative descriptions below in your Table E/E1 at M2 and if there is no corresponding funding request, then simply leave the value cell blank. <b>(Action Point 1.14)</b></p> <table border="1" data-bbox="168 785 1377 1244"> <thead> <tr> <th data-bbox="168 785 1086 869">FDU 'Other' Covid-19 Expenditure Categories (all to be added to Table E):</th><th data-bbox="1086 785 1377 869">Table E - Covid-19 Section Line ref:</th></tr> </thead> <tbody> <tr> <td data-bbox="168 869 1086 909">A2. Increased bed capacity specifically related to C-19</td><td data-bbox="1086 869 1377 909">69</td></tr> <tr> <td data-bbox="168 909 1086 949">A3. Other Capacity &amp; facilities costs (exclude contract cleaning)</td><td data-bbox="1086 909 1377 949">70</td></tr> <tr> <td data-bbox="168 949 1086 989">B1. Prescribing charges directly related to COVID symptoms</td><td data-bbox="1086 949 1377 989">71</td></tr> <tr> <td data-bbox="168 989 1086 1061">C1. Increased workforce costs as a direct result of the COVID response and IP&amp;C guidance</td><td data-bbox="1086 989 1377 1061">72</td></tr> <tr> <td data-bbox="168 1061 1086 1101">D1. Discharge Support</td><td data-bbox="1086 1061 1377 1101">73</td></tr> <tr> <td data-bbox="168 1101 1086 1141">D4. Support for National Programmes through Shared Service</td><td data-bbox="1086 1101 1377 1141">74</td></tr> <tr> <td data-bbox="168 1141 1086 1181">D5. Other Services that support the ongoing COVID response</td><td data-bbox="1086 1141 1377 1181">75</td></tr> <tr> <td data-bbox="168 1181 1086 1244">E1. Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS Income</td><td data-bbox="1086 1181 1377 1244">76</td></tr> </tbody> </table>	FDU 'Other' Covid-19 Expenditure Categories (all to be added to Table E):	Table E - Covid-19 Section Line ref:	A2. Increased bed capacity specifically related to C-19	69	A3. Other Capacity & facilities costs (exclude contract cleaning)	70	B1. Prescribing charges directly related to COVID symptoms	71	C1. Increased workforce costs as a direct result of the COVID response and IP&C guidance	72	D1. Discharge Support	73	D4. Support for National Programmes through Shared Service	74	D5. Other Services that support the ongoing COVID response	75	E1. Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS Income	76	This has been completed in Table E.
FDU 'Other' Covid-19 Expenditure Categories (all to be added to Table E):	Table E - Covid-19 Section Line ref:																		
A2. Increased bed capacity specifically related to C-19	69																		
A3. Other Capacity & facilities costs (exclude contract cleaning)	70																		
B1. Prescribing charges directly related to COVID symptoms	71																		
C1. Increased workforce costs as a direct result of the COVID response and IP&C guidance	72																		
D1. Discharge Support	73																		
D4. Support for National Programmes through Shared Service	74																		
D5. Other Services that support the ongoing COVID response	75																		
E1. Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS Income	76																		
Please ensure that funding associated with forecast cleaning standards expenditure reported in Table B3, is reported within the designated line (67) of Table E, as this impact when we consolidate the All-Wales data. <b>(Action Point 1.15)</b>	This has been completed in Table E.																		

Hywel Dda ULHB				Period : May 22	
Table A - Movement of Operating Financial Plan to Forecast Outturn					
This Table is currently showing 0 errors					
Line 14 should reflect the corresponding amounts included within the latest MTP/AOP submission to WG					
Lines 1 - 14 should not be adjusted after Month 1					
	In Year Effect	Non Recurring	Recurring	FYE of Recurring	
	£'000	£'000	£'000	£'000	
1	Underlying Position bnfed from Previous Year - must agree to M12 MMR (Deficit - Negative Value)	-68,888	0	-68,888	-68,888
2	Planned New Expenditure (Non Covid-19) (Negative Value)	-50,122	-10,660	-39,462	-39,462
3	Planned Expenditure For Covid-19 (Negative Value)	-31,385	-31,385	0	0
4	Planned Welsh Government Funding (Non Covid-19) (Positive Value)	64,844	-10,000	53,844	53,844
5	Planned Welsh Government Funding for Covid-19 (Positive Value)	31,385	31,385	0	0
6	Planned Capital Income (Positive Value)	0	0	0	0
7	RRL Profile - planning only (In Year Effect / Column C must be nil)	-77	68	-715	-81
8	Planned (Finalised) Savings Plan	12,366	12,061	305	487
9	Planned (Finalised) Net Income Generation	0	0	0	0
10	Planned Profit / (Loss) on Disposal of Assets	0	0	0	0
11	Planned Release of Uncommitted Contingencies & Reserves (Positive Value)	0	0	0	0
12		0	0	0	0
13	Planning Assumptions still to be finalised at Month 1	17,000	17,000	0	0
14	Opening MTP / Annual Operating Plan	-25,000	29,981	-54,061	-53,889
15	Reversal of Planning Assumptions still to be finalised at Month 1	-17,000	-17,000	0	0
16	Additional In Year & Movement from Planned Release of Previously Committed Contingencies & Reserves (Positive Value)	0	0	0	0
17	Additional In Year & Movement from Planned Profit / (Loss) on Disposal of Assets	0	0	0	0
18	Other Movement in Month 1 Planned & In Year Net Income Generation	0	0	0	0
19	Overschivement	0	0	0	0
20	Additional in Year Identified Savings - Forecast	0	0	0	0
21	Variance to Planned RRL & Other Income	-1	-1	0	0
22	Additional In Year & Movement in Planned Welsh Government Funding for Covid-19 (Positive Value - additional)	1,236	1,236	0	0
23	Additional In Year & Movement in Planned Welsh Government Funding (Non Covid) (Positive Value - additional)	0	0	0	0
24	Additional In Year & Movement Expenditure for Covid-19 (Negative Value - additional/Positive Value - reduction)	-1,236	-1,236	0	0
25	In Year Accounting Gains (Positive Value)	0	0	0	0
26	Net In Year Operational Variance to MTP/AOP (material gross amounts to be listed separately)	0	0	0	0
27	Unscheduled Care and Facilities and Radiology operational pressures	-1,714	-1,714		
28	Unidentified savings to mitigate operational pressures	1,714	1,714		
29		0	0	0	0
30					
31		0	0		
32		0	0		
33		0	0		
34		0	0		
35		0	0		
36		0	0		
37		0	0		
38		0	0		
39		0	0		
40	Forecast Outturn (- Deficit / + Surplus)	-42,000	12,061	-54,061	-53,889
41	Covid-19 - Forecast Outturn (- Deficit / + Surplus)	0			
42	Operational - Forecast Outturn (- Deficit / + Surplus)	-42,000			

	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	YTD	In Year Effect
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
1	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-11,481	-68,888
2	-4,083	-4,083	-4,083	-4,141	-4,141	-4,141	-4,242	-4,242	-4,242	-4,242	-4,242	-4,242	-8,166	-50,122
3	-2,896	-2,896	-2,736	-2,500	-2,534	-2,545	-2,512	-2,543	-2,563	-2,555	-2,541	-2,564	-5,762	-31,385
4	5,397	5,397	5,397	5,397	5,397	5,397	5,397	5,397	5,397	5,397	5,397	5,397	10,714	64,844
5	2,896	2,896	2,736	2,500	2,534	2,545	2,512	2,543	2,563	2,555	2,541	2,564	5,762	31,385
6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	-77	68	-715	-81	232	247	-224	92	306	-134	192	73	-9	0
8	1,013	869	1,652	1,075	743	748	1,319	1,004	789	1,229	803	1,022	1,882	12,366
9	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	1,417	1,417	1,417	1,417	1,417	1,417	1,417	1,417	1,417	1,417	1,417	1,417	2,833	17,000
14	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-2,083	-4,167	-25,000
15	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-1,417	-2,833	-17,000
16	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0	0	0	0
21	0	0	100	171	-181	-251	452	120	-116	229	-109	-438	0	-1
22	0	456	-31	99	82	158	92	89	90	64	67	70	456	1,236
23	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	0	-456	31	-99	-82	-158	-92	-89	-90	-64	-67	-70	-456	-1,236
25	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27	-946	-768											-1,714	-1,714
28	0	0	0	0	0	0	0	286	286	286	286	286	0	1,714
29	0	0	0	0	0	0	0	0	0	0	0	0	0	0
30													-84	-142
31													0	0
32													0	0
33													0	0
34													0	0
35													0	0
36													0	0
37													0	0
38													0	0
39													0	0
40	-4,446	-4,268	-3,400	-3,329	-3,661	-3,761	-2,761	-3,094	-3,331	-2,866	-3,324	-3,650	-8,714	-42,000
41	0	0	0	0	0	0	0	0	0	0	0	0	0	0
42	-4,446	-4,268	-3,400	-3,329	-3,661	-3,761	-2,761	-3,094	-3,331	-2,866	-3,324	-3,650	-8,714	-42,000

Table A1 - Underlying Position

Section A - By Spend Area		Full Year Effect of Actions			Net Accounting Year Effect of Undigested Payments (£m)	IMTP Underlying Position of £'000
		IMTP Underlying Position of £'000	Recurring Savings (£m)	Recurring Allocations (Income) (£m)		
1	Pay - Administration, Clinical & Board Members	(264)			(264)	(264)
2	Pay - Medical & Dental	(10,496)		6,330	(4,166)	(4,166)
3	Pay - Nursing & Midwifery Registered	(6,552)		1,821	(4,731)	(4,731)
4	Pay - Prof Scientific & Technical	(1,814)		500	(1,314)	(1,314)
5	Pay - Additional Clinical Services	(3,131)		3,918	8	8
6	Pay - Allied Health Professionals	1,874			1,874	1,874
7	Pay - Healthcare Support Staff	99			99	99
8	Pay - Estates & Facilities	25			25	25
9	Pay - Students	0			0	0
10	Non Pay - Supplies and services - clinical	(12,140)		2,400	(9,740)	(9,740)
11	Non Pay - Supplies and services - general	(1,419)			(1,419)	(1,419)
12	Non Pay - Consumables Services	(832)			(832)	(832)
13	Non Pay - Entertainment	(985)			(985)	(985)
14	Non Pay - Transport	(4,129)			(4,129)	(4,129)
15	Non Pay - Premises	(8,126)			(8,126)	(8,126)
16	Non Pay - External Contractors	(1,889)			(1,889)	(1,889)
17	Health Care Provided by other Orgs - Welsh LHBs	(5,197)			(5,197)	(5,197)
18	Health Care Provided by other Orgs - Welsh Trusts	(1,738)			(1,738)	(1,738)
19	Health Care Provided by other Orgs - NHS/SC	(12,258)			(12,258)	(12,258)
20	Health Care Provided by other Orgs - English	0			0	0
21	Health Care Provided by other Orgs - Private / Other	(6,607)			(6,607)	(6,607)
22	Total	(65,888)	0	14,959	(50,929)	(50,929)

Section B - By Directorate		Full Year Effect of Actions			Net Accounting Year Effect of Undigested Payments (£m)	IMTP Underlying Position of £'000
		IMTP Underlying Position of £'000	Recurring Savings (£m)	Recurring Allocations (Income) (£m)		
1	Primary Care	(1,165)			(1,165)	(1,165)
2	Mental Health	1,810			1,810	1,810
3	Community Health Care	(1,264)			(1,264)	(1,264)
4	Commissioned Services	(11,817)			(11,817)	(11,817)
5	Unscheduled Care	(11,969)		7,088	(4,881)	(4,881)
6	Unscheduled Care	(24,000)		7,088	(16,912)	(16,912)
7	Children & Young People's	(5,365)			(5,365)	(5,365)
8	Community Services	73			73	73
9	Specialised Services	(8,167)			(8,167)	(8,167)
10	Emergency & Corporate Areas	(3,176)			(3,176)	(3,176)
11	Support Services (inc. Estates & Facilities)	(1,223)			(1,223)	(1,223)
12	Total	(68,888)	0	14,959	(53,929)	(53,929)

Table A2 - Overview Of Key Risks & Opportunities		FORECAST YEAR END	
		£'000	Likelihood
Opportunities to achieve IMTP/AOP (positive values)			
1	Rad Pipeline schemes (inc AG & IG)		
2	Potential Cost Reduction		
3	Total Opportunities to achieve IMTP/AOP	0	
Risks (negative values)			
4	Under Delivery of Amber Schemes included in Outturn via Tracker	(1,120)	Medium
5	Continuing Healthcare		
6	Prescribing		
7	Pharmacy Contract		
8	WHS&C Performance		
9	Other Contract Performance		
10	GMS Ring Fenced Allocation Underspend Potential Claw back		
11	Dental Ring Fenced Allocation Underspend Potential Claw back		
12	Operational variation trend risk	(10,000)	Medium
13	COVID-19 transitional funding not yet confirmed	(16,424)	Low
14	Extrabudgetary items funding not yet confirmed	(11,069)	Low
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26	Total Risks	(38,513)	
Further Opportunities (positive values)			
27	Target Operating Model		
28			
29			
30			
31			
32			
33			
34	Total Further Opportunities	0	
35	Current Reported Forecast Outturn	(42,000)	
36	IMTP / AOP Outturn Scenario	(42,000)	
37	Worst Case Outturn Scenario	(81,513)	
38	Best Case Outturn Scenario	(42,000)	

Table B - Monthly Positions

		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position		
A. Monthly Summarised Statement of Comprehensive Net Expenditure / Statement of Comprehensive Net Income		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000		
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000		
1	Revenue Reserves/Loan	Actual/Foast	85,768	84,841	83,395	84,129	80,084	84,725	85,222	85,865	85,431	86,645	84,342	81,656	188,609	1,055,105	
2	Capital Donations (Government Grant Income (Health Board only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	Wages NHS Local Health Boards & Trusts Income	Actual/Foast	2,476	2,620	2,800	2,800	2,800	2,800	2,800	2,800	2,800	2,800	2,800	2,800	5,000	33,094	
4	WHS&C Income	Actual/Foast	201	228	214	214	214	214	214	214	214	214	214	214	428	2,603	
5	Waste Government Income (Non RRS)	Actual/Foast	453	(147)	128	128	128	128	128	128	128	128	128	128	256	1,338	
6	Other Income	Actual/Foast	732	2,372	1,824	2,307	2,464	2,408	2,411	2,416	2,416	2,426	2,431	2,431	11,116	28,433	
7	Income Total	Actual/Foast	89,641	89,487	88,359	89,486	85,633	88,957	91,789	91,418	90,988	92,207	90,909	87,225	178,603	1,485,741	
8	Primary Care - Consultant (including drugs, including non resource limited expenditure)	Actual/Foast	12,121	10,285	9,354	9,354	9,354	9,354	9,354	9,354	9,354	10,621	9,559	10,411	22,160	137,728	
9	Primary Care - Drugs & Appliances	Actual/Foast	6,370	6,744	6,370	6,370	6,657	7,225	6,657	6,657	6,657	6,335	5,832	6,804	13,480	79,208	
10	Provided Services - Pay	Actual/Foast	42,871	45,135	42,142	42,785	42,792	42,873	42,838	42,812	42,865	43,186	42,821	40,187	84,906	513,330	
11	Private Services - Non Pay (including drugs & depreciation)	Actual/Foast	8,474	8,830	8,358	8,435	8,364	8,804	8,807	8,873	9,308	9,380	9,439	9,223	17,005	109,260	
12	Secondary Care - Drugs	Actual/Foast	3,978	4,804	3,982	4,461	4,467	4,463	4,463	4,394	4,394	4,377	4,394	4,624	8,980	52,571	
13	Healthcare Services Provided by Other NHS Bodies	Actual/Foast	14,138	14,203	14,268	14,214	14,214	14,214	14,214	14,214	14,214	14,214	14,214	14,214	29,371	170,560	
14	Non Healthcare Services Provided by Other NHS Bodies	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
15	Contracting Care and Funded Nursing Care	Actual/Foast	4,160	4,327	4,217	4,608	4,608	4,717	4,608	4,717	4,608	4,608	4,608	4,608	9,000	56,119	
16	Other Private & Voluntary Sector	Actual/Foast	79	543	230	230	230	230	230	230	230	230	230	230	615	2,915	
17	Joint Financing and Other	Actual/Foast	108	85	114	114	114	114	114	114	114	114	114	114	201	1,265	
18	Losses, Special Payments and Inconvertible Debt	Actual/Foast	129	127	143	143	143	143	143	143	143	143	143	143	255	1,685	
19	Exceptional Income / Costs - (Trust Only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
20	Total Interest Receivable - (Trust Only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
21	Total Interest Payable - (Trust Only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
22	RRS Depreciation/Accelerated Depreciation/Impairments	Actual/Foast	2,033	2,038	2,038	2,041	2,041	2,041	2,041	2,036	2,036	1,497	2,568	2,029	2,025	4,061	
23	AME Donated Depreciation/Impairments	Actual/Foast	62	62	62	62	61	61	61	60	60	59	59	59	124	728	
24	Uncommitted Reserves & Contingencies	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
25	Profit/Loss Disposal of Assets	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
26	Cost - Total	Actual/Foast	82,487	82,728	82,282	82,487	82,391	84,288	84,530	84,612	84,519	85,183	82,232	82,478	167,232	1,127,741	
27	Net surplus/ (deficit)	Actual/Foast	(1,446)	(1,486)	(1,456)	(1,529)	(1,461)	(1,375)	(1,341)	(1,351)	(1,351)	(1,406)	(1,434)	(1,456)	(1,114)	(12,466)	
B. Cost Total by Directorate		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position		
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000		
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000		
28	Primary Care	Actual/Foast	10,051	9,733	9,394	9,054	9,053	9,114	9,569	9,836	9,447	9,917	9,790	9,449	10,131	19,787	
29	Mental Health	Actual/Foast	5,039	5,182	5,054	5,064	5,061	5,061	5,521	5,521	5,521	5,521	5,521	5,521	10,202	63,564	
30	Community Healthcare	Actual/Foast	4,329	4,327	4,327	4,327	4,327	4,327	4,329	4,329	4,329	4,329	4,329	4,329	8,658	54,571	
31	Commissioned Services	Actual/Foast	13,323	13,417	13,424	13,424	13,424	13,424	13,424	13,424	13,424	13,424	13,424	13,424	26,765	160,984	
32	Subsidiary Care	Actual/Foast	9,403	9,968	9,745	10,057	10,050	10,379	10,324	10,324	10,328	10,371	10,378	10,372	19,371	121,794	
33	Uncontracted Care	Actual/Foast	12,353	12,711	12,671	12,788	12,788	12,889	12,881	12,880	12,880	12,454	12,300	12,647	25,064	150,700	
34	Children & Women's	Actual/Foast	3,477	3,844	3,595	3,582	3,580	3,585	3,604	3,620	3,584	3,589	3,595	3,570	7,341	43,344	
35	Community Services	Actual/Foast	5,969	6,168	6,040	6,037	6,037	6,091	6,066	6,027	6,025	6,035	6,037	6,037	12,074	78,285	
36	Specialised Services	Actual/Foast	14,880	14,977	14,922	14,973	14,930	15,103	15,279	15,148	14,811	14,369	14,022	15,205	29,958	178,002	
37	Executive - Corporate Areas	Actual/Foast	7,724	6,944	7,025	7,123	7,034	6,838	6,320	6,324	6,323	6,702	6,664	6,678	14,468	82,368	
38	Support Services (inc. Estates & Facilities)	Actual/Foast	4,860	4,375	4,394	3,940	3,940	3,941	3,958	4,012	4,002	4,001	4,015	4,007	8,230	55,675	
39	Reserves	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
40	Cost - Total (excluding DEL & AME Non-Cash Charges)	Actual/Foast	81,262	81,646	80,216	80,906	81,189	82,538	82,538	82,417	82,761	82,568	81,144	83,787	163,037	1,162,605	
C. Assessment of Financial Forecast Positions		Year-to-date YTD														Full year surplus/ (deficit) scenarios	
		£'000														£'000	
28. Actual YTD surplus/ (deficit)		(8,714)														13. Extrapolated Scenario	
29. Actual YTD surplus/ (deficit) last month		(4,446)														(12,094)	
30. Current month actual surplus/ (deficit)		(4,205)														14. Year to Date Trend Scenario	
31. Average monthly surplus/ (deficit) YTD		(4,357)														Trend	
32. YTD remaining months		(871)														A	
																B	
D. DEL/AME Depreciation & Impairments		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position		
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000		
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000		
DEL		Actual/Foast	1,328	1,328	1,328	1,335	1,335	1,338	1,331	1,331	792	1,888	1,327	1,327	2,654	15,985	
35	Baseline Provider Depreciation	Actual/Foast	428	428	428	428	428	428	428	428	428	428	428	428	856	5,571	
36	Strategic Depreciation	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
37	Accelerated Depreciation	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
38	Impairments	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
39	IFRS 16 Leases	Actual/Foast	207	204	206	207	207	208	207	207	207	207	207	209	411	2,480	
40	Total	Actual/Foast	2,633	2,625	2,655	2,641	2,641	2,641	2,636	2,636	1,497	2,985	2,029	2,025	4,961	24,471	
AME		Actual/Foast	62	62	62	61	61	61	60	60	61	59	59	60	124	728	
41	Donated Asset Depreciation	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
42	Impairments (including Reserves)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
43	IFRS 16 Leases	Actual/Foast	62	62	62	61	61	61	60	60	61	59	59	60	124	728	
44	Total	Actual/Foast	62	62	62	61	61	61	60	60	61	59	59	60	124	728	
D. Accountancy Gains		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position		
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000		
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000		
45	Accountancy Gains	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
E. Committed Reserves & Contingencies		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position		
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000		
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000		
List of all Committed Reserves & Contingencies inc above in Section A. Please specify Row number in description.		Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
46	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
47	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
48	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
49	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
50	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
51	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
52	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
53	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
54	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
55	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
56	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
57	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
58	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
59	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
60	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
61	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
62	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
63	Forecast Only	Forecast Only	0	0	0	0	0	0	0	0	0	0					

Table B2 - Pay Expenditure Analysis

A - Pay Expenditure																
REF	TYPE	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position	
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000			
1	Administrative, Clinical & Board Members	6,415	6,432	6,503	6,506	6,426	6,451	6,445	6,409	6,450	6,452	6,464	6,419	6,408	12,848	77,105
2	Medical & Dental	9,365	9,366	9,351	9,329	9,219	9,353	9,329	9,322	9,322	9,322	9,322	9,322	9,322	19,730	111,646
3	Nursing & Midwifery Registered	13,881	13,881	14,103	14,402	14,412	14,410	14,413	14,406	14,406	14,404	14,396	14,381	14,375	27,488	171,142
4	Prof Scientific & Technical	1,306	1,375	1,633	1,645	1,642	1,642	1,638	1,638	1,638	1,638	1,638	1,638	1,638	2,681	19,074
5	Additional Clinical Services	6,122	6,025	6,023	6,100	6,146	6,106	6,130	6,130	6,130	6,130	6,123	6,100	6,095	12,146	73,522
6	Allied Health Professionals	3,043	3,041	2,697	2,615	2,729	2,684	2,689	2,690	2,691	2,725	2,705	2,702	2,697	6,083	33,615
7	Healthcare Scientists	879	863	864	877	877	877	872	872	872	872	872	872	872	1,942	11,883
8	Estates & Ancillary	2,009	2,432	2,328	2,366	2,351	2,296	2,308	2,328	2,348	2,365	2,368	2,388	2,388	4,841	35,365
9	Students	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	TOTAL PAY EXPENDITURE	43,822	43,223	43,228	43,883	43,895	43,976	43,930	44,016	44,073	44,216	44,028	44,381	44,345	86,845	526,403
Analysis of Pay Expenditure																
11	L100 Protected Services - Pay	42,671	42,155	42,142	42,286	42,192	42,873	42,608	42,912	42,865	43,106	42,851	43,187	43,187	84,834	507,895
12	Other Services (incl. Primary Care) - Pay	952	1,068	1,086	1,103	1,103	1,104	1,104	1,106	1,108	1,110	1,113	1,194	1,194	2,020	12,833
13	Total - Pay	43,623	43,223	43,228	43,888	43,895	43,976	43,930	44,016	44,073	44,216	44,028	44,381	44,381	86,848	526,529
B - Agency / Locum (premium) Expenditure																
- Analysed by Type of Staff																
REF	TYPE	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position	
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000			
1	Administrative, Clinical & Board Members	27	28	21	12	2	2	2	2	2	2	2	2	80	86	
2	Medical & Dental	400	646	500	550	550	550	550	550	550	550	550	550	1,115	6,835	
3	Nursing & Midwifery Registered	1,871	2,109	2,271	2,371	2,371	2,371	2,371	2,371	2,371	2,371	2,368	2,371	3,780	27,883	
4	Prof Scientific & Technical	2	2	2	2	2	2	2	2	2	2	2	2	5	5	
5	Additional Clinical Services	2	2	2	2	2	2	2	2	2	2	2	2	5	181	
6	Allied Health Professionals	125	131	130	130	130	130	130	130	130	130	130	130	286	1,562	
7	Healthcare Scientists	48	35	21	14	14	14	14	14	14	14	14	14	77	188	
8	Estates & Ancillary	16	6	7	7	7	7	7	7	7	7	7	7	22	91	
9	Students	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	TOTAL AGENCY/LOCUM (PREMIUM) EXPENDITURE	2,372	2,863	3,017	3,191	3,091	3,091	3,086	3,086	3,086	3,086	3,081	3,086	5,325	36,134	
11	Agency/Locum (premium) % of pay	5.4%	6.6%	7.0%	7.3%	7.0%	7.0%	7.0%	7.0%	7.0%	7.0%	7.0%	7.0%	6.1%	6.9%	
C - Agency / Locum (premium) Expenditure																
- Analysed by Reason for Using Agency/Locum (premium)																
REF	REASON	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position	
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000			
1	Vacancy	1,858	2,307	2,424	2,504	2,495	2,495	2,495	2,495	2,495	2,495	2,491	2,495	4,185	29,051	
2	Maternity/Parental/Adoption Leave	0	0	0	0	0	0	0	0	0	0	0	0	14	93	
3	Special Leave (Paid) - inc. compassionate leave, interview	2	3	3	3	3	3	3	3	3	3	3	3	6	33	
4	Special Leave (Unpaid)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
5	Study Leave/Examinations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
6	Additional Activity (Other Pressures/Other Pressures)	0	238	241	262	247	247	247	247	247	247	247	247	458	2,681	
7	Annual Leave	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
8	Sickness	56	72	75	76	76	76	76	76	76	76	77	76	76	129	
9	Respite/Cover	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10	Jury Service	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
11	WJ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
12	Exclusion (Suspension)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
13	COVID-19	256	327	285	285	285	285	285	285	285	285	285	285	881	3,168	
14	TOTAL AGENCY/LOCUM (PREMIUM) EXPENDITURE	2,372	2,863	3,017	3,191	3,091	3,091	3,086	3,086	3,086	3,086	3,081	3,086	5,325	36,134	

Table B3 - COVID-19 Analysis

A - Additional Expenditure																
	1	2	3	4	5	6	7	8	9	10	11	12				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Total YTD	Forecast year-end		
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
<b>1</b>	<b>Enter as positive values - actual/forecast</b>															
<b>2</b>	<b>Provider Pay (Establishment, Temp &amp; Agency)</b>															
3	18	10	15	15	15	15	15	15	15	15	15	15	15	22	175	
4														0	0	
5	25	20	30	30	30	30	30	30	30	30	30	30	30	4	0	
6														0	0	
7	24	81	75	75	75	75	75	75	75	75	75	75	75	155	0	
8														0	0	
9														0	0	
10														0	0	
11														0	0	
12														0	0	
13	127	120	120	140	140	140	140	140	140	140	140	140	140	141	1,681	
14														0	0	
15														0	0	
16	34	10	10	10	10	10	10	10	10	10	10	10	10	44	144	
17														0	0	
18														0	0	
19														0	0	
20														0	0	
21														0	0	
22														0	0	
23														0	0	
24														0	0	
25														0	0	
26	34	10	10	10	10	10	10	10	10	10	10	10	10	44	144	
27	161	130	130	150	150	150	150	150	150	150	150	150	150	201	1,621	
28	101	140	140	150	150	150	150	150	150	150	150	150	150	151	1,824	
29	0	10	10	10	10	10	10	10	10	10	10	10	9	10	103	
30	<b>Provider Pay (Establishment, Temp &amp; Agency)</b>															
31	6	6	5	5	5	5	5	5	5	5	5	5	5	12	62	
32	8	8	8	8	8	8	8	8	8	8	8	8	8	5	46	
33	11	7	10	10	10	10	10	10	10	10	10	10	10	18	118	
34														0	0	
35														0	0	
36	1	1												2	2	
37														0	0	
38														0	0	
39														0	0	
40														0	0	
41	28	22	21	21	21	21	21	21	15	15	15	15	15	46	228	
42														0	0	
43														0	0	
44										1	1	1	1	0	4	
45	4	4	4	4	4	4	4	4	4	4	4	4	4	0	46	
46														0	0	
47														0	0	
48														0	0	
49														0	0	
50	320	400	280	280	275	275	275	261	261	261	261	261	261	729	2,020	
51														0	0	
52														0	0	
53														0	0	
54	324	410	290	290	277	277	277	266	266	266	266	266	266	727	2,012	
55	330	435	311	311	298	298	298	286	286	286	286	286	286	755	2,000	
56	100	340	105	105	105	105	105	105	105	105	105	105	200	655	2,000	
57	0	10	10	10	10	10	10	10	10	10	10	10	9	10	103	
58	<b>Mass COVID-19 Vaccination Additional costs due to C19 enter as positive values - actual/forecast</b>															
59	<b>Provider Pay (Establishment, Temp &amp; Agency)</b>															
60	96	110	131	129	129	130	130	140	140	140	140	140	140	215	1,689	
61														0	0	
62	255	234	248	254	259	259	259	259	259	259	259	259	259	489	3,063	
63	3	5	1	5	5	5	5	5	5	5	5	5	5	0	0	
64	130	110	125	125	125	125	125	125	125	125	125	125	125	245	1,485	
65	21	25	20	24	24	24	24	24	24	24	24	24	24	44	280	
66														0	0	
67	9	9	9	9	9	9	9	9	9	9	9	9	9	18	108	
68														0	0	
69	519	550	534	544	549	550	550	580	580	580	580	580	580	1,024	6,555	
70														0	0	
71														0	0	
72	125	155	130	130	130	130	130	130	130	130	130	130	130	280	1,650	
73														0	0	
74														0	0	
75														0	0	
76														0	0	
77														0	0	
78														0	0	
79														0	0	
80														0	0	
81														0	0	
82	125	237	130	130	130	130	130	130	130	130	130	130	130	412	1,944	
83	444	792	664	674	679	744	744	744	744	699	699	699	699	1,418	4,529	
84	644	738	665	683	691	691	691	691	691	691	691	691	691	1,382	3,293	
85	0	240	5	5	5	12	601	601	601	601	601	601	601	10	2,040	
86	<b>Extended Flu Vaccination Additional costs due to C19 enter as positive values - actual/forecast</b>															
87	<b>Provider Pay (Establishment, Temp &amp; Agency)</b>															
88														0	0	
89														0	0	
90														0	0	
91														0	0	
92														0	0	
93														0	0	
94														0	0	
95														0	0	
96	0	0	0	0	0	0	0	0	0	0	0	0	0	4	10	
97														0	0	
98														0	0	
99														0	0	
100														0	0	
101														0	0	
102														0	0	
103														0	0	
104														0	0	
105														0	0	
106														0	0	
107														0	0	
108														0	0	
109														0	0	
110	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
111	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
112	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
113	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	





Table C - Identified Expenditure Savings Schemes (Excludes Income Generation & Accountancy Gains)

		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Full-year forecast	FTD as %age of FY F10 variance as %age of FTD Budget/Fair	Assessment		Full In-Year forecast		Full-Year Effect of Resource Savings £'000
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000				Green £'000	Amber £'000	non recording £'000	recording £'000	
1	Budget/Fair	0	0	0	0	0	0	0	200	0	0	0	0	0	200	0	0	200	0	0	
2	Actual/Fair	0	0	0	0	0	0	0	200	0	0	0	0	0	200	0.00%	0	200	200	0	0
3	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
4	Budget/Fair	100	100	100	100	100	100	100	100	100	100	100	100	200	1,200	18.63%	1,200	0	1,200	0	0
5	Actual/Fair	100	100	100	100	100	100	100	100	100	100	100	100	200	1,200	0	0	0	1,200	0	0
6	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
7	Budget/Fair	49	48	53	51	49	53	48	51	53	148	148	153	95	900	50.51%	303	600	900	0	0
8	Actual/Fair	49	48	53	51	49	53	48	51	53	148	148	153	95	900	0	0	0	900	0	0
9	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10	Budget/Fair	43	43	50	46	40	67	61	86	78	423	100	211	88	3,070	2.92%	1,064	1,446	2,758	254	365
11	Actual/Fair	43	43	50	46	40	67	61	86	78	423	100	211	88	3,070	0	0	0	0	0	0
12	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
13	Budget/Fair	821	879	599	599	528	528	557	557	558	558	557	558	1,499	7,058	21.24%	3,701	3,355	7,005	51	102
14	Actual/Fair	821	879	599	599	528	528	557	557	558	558	557	558	1,499	7,058	0	0	0	0	0	0
15	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
16	Budget/Fair	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	Actual/Fair	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	Budget/Fair	1,013	869	1,052	1,075	743	748	1,319	1,004	789	1,229	993	1,022	1,882	12,368	15.22%	6,785	5,607	12,061	305	467
20	Actual/Fair	1,013	869	1,052	1,075	743	748	1,319	1,004	789	1,229	993	1,022	1,882	12,368	0	0	0	0	0	0
21	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
22	Variance in month	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%						
23	In month achievement against	8.39%	7.02%	13.38%	8.70%	6.01%	6.05%	10.67%	8.12%	6.38%	9.94%	7.30%	8.27%								

Table D - Income/Expenditure Assumptions						
Annual Forecast						
LHB/Trust		Contracted Income	Non Contracted Income	Total Income	Contracted Expenditure	Non Contracted Expenditure
		£'000	£'000	£'000	£'000	£'000
1	Swansea Bay University	3,869	529	4,398	36,272	3,295
2	Aneurin Bevan University	368	627	995	300	16
3	Betsi Cadwaladr University	4,991	179	5,170	238	4
4	Cardiff & Vale University	338	278	617	5,740	834
5	Coventry & Warwickshire University	487	86	566	483	297
6	Hywel Dda University			0		
7	Phryni	7,810	1,047	8,857	198	70
8	Public Health Wales	2,738	442	3,180	1,708	563
9	Valindia		5,136	5,136	15,059	7,431
10	NHSUW			0		
11	DHCUW	715		715	3,145	1,058
12	Wales Ambulance Services		417	417	2,334	3,009
13	WHHS	1,708		1,708	84,443	(80)
14	EASU		8,240	8,240	31,254	
15	HEW			0		
16	NHS Wales Executive			0		
17	Total	23,162	16,994	40,156	181,242	16,491

Table E - Resource Limits		STATUS OF ISSUED RESOURCE LIMIT ITEMS				Total Revenue or Resource Limit	Recurring (R) or Non Recurring (NR)	Total Revenue Drawing Limit	Total Capital Resource Limit	Total Capital Drawing Limit
1. BASE ALLOCATION		HCHS £'000	Pharmacy £'000	Dental £'000	GMS £'000	£'000		£'000	£'000	£'000
1. LATEST ALLOCATION LETTER/SCHEDULE REF:		1	1	1	1	1		1		1
2. Total Confirmed Funding		841,197	21,889	18,735	73,081	954,882		939,564	28,951	28,951
2. ANTICIPATED ALLOCATIONS										
3. DEL Non Cash Depreciation - Baseline Surplus / Shortfall			642			642				
4. DEL Non Cash Depreciation - Buildings			5,970			5,970				
5. DEL Non Cash Depreciation - Accelerated						0				
6. DEL Non Cash Depreciation - Impairment						0				
7. DEL Non Cash Depreciation - IFRS 16 Leases			2,481			2,481				
8. AME Non Cash Depreciation - IFRS 16 Leases (Peppercom)						0				
9. AME Non Cash Depreciation - Donated Assets			728			728				
10. AME Non Cash Depreciation - Impairment						0				
11. AME Non Cash Depreciation - Impairment Reversals						0				
12. Removal of Donated Assets / Government Grant Receipts						0				
13. Total COVID-19 (see below analysis)			32,621	0	0	32,621			32,621	
14. Removal of IFRS 16 Leases (Revenue)						0				
15. Energy (Price Increases)			5,843			5,843	NR		5,843	
16. Employers NI Increases (1.25%)			3,086			3,086	R		3,086	
17. Road User Charge			3,040			3,040	R		3,040	
18. Children & Young Peoples Mental Health & Emotional Wellbeing			200			200	R		200	
19. CAMHS to reach school support BR (Rev 20-23)			711			711	R		711	
20. All age Mental Health - Tier 0/1 provision			200			200	R		200	
21. Memory Assessment Services West Wales area			384			384	R		384	
22. EASC/WAST Improvements in MHE emergency calls			42			42	R		42	
23. Substance Misuse			2,138			2,138	R		2,138	
24. Pharmacy, Delivering a Healthier Wales - Digital Signposting Tool			20			20	R		20	
25. ICF Dementia			1,249			1,249	R		1,249	
26.						0				
27. WHISC CAMHS			86			86	R		86	
28. Urgent and Emergency Care			2,800			2,800	R		2,800	
29. Subacute Mental 2022-23 appt			126			126	R		126	
30. Neighbourhood District Funding: Diabetic Nurse Specialist (Yr 2 of 2)			29			29	NR			
31. Neighbourhood District Funding: Development of a Peer Coach Role for District Nursing (Yr 2 of 3)			88			88	NR			
32. Neighbourhood District Funding: Development of Community HCGW Workforce (Yr 2 of 3)			95			95	NR			
33. Six Goals for Urgent and Emergency Care Programme: Six Goals Improvement Triumvirate Td Prevention			160			160	NR			
34.			142			142	NR			
35. Carers			121			121	NR			
36. HWWH (Healthier Weight, Healthier Wales, Obesity)			374			374	NR			
37. PACU			904			904	R		904	
38. Transfer of budget to WAST			(3,143)			(3,143)	R		(3,143)	
39. MHLd Alternatives to admission			512			512	NR			
40. MHLd Living Disorders			320			320	NR			
41. MHLd Service Improvement Funding			1,279			1,279	NR			
42. MHLd Primary Care Lesson and Tier 0/1			639			639	NR			
43. Welsh Risk Pool			(2,686)			(2,686)	NR		(2,686)	
44. Dental PCR			1,089			1,089	NR			
45. OHS pay and expenses 2021-22					1,329	1,329	R			
46. B1-2 Pay Award			189			189	R			
47. Overtime during Annual Leave (MT-12 2021/22)			153			153	R			
48. Value Based Health Care			375			375	NR			
49. Outpatients Recovery Q1-2			277			277	NR			
50.						0				
51. Total Anticipated Funding		63,894	0	0	1,329	65,223		65,402	0	0
3. TOTAL RESOURCES & BUDGET RECONCILIATION										
52. Confirmed Resources Per 1. above		841,197	21,889	18,735	73,081	954,882		939,564	28,951	28,951
53. Anticipated Resources Per 2. above		63,894	0	0	1,329	65,223		65,402	0	0
54. Total Resources		905,091	21,889	18,735	74,410	1,020,105		994,966	28,951	28,951
ANALYSIS OF WG FUNDING FOR COVID-19 INCLUDED ABOVE		Allocated Total £'000	Anticipated HCHS £'000	Anticipated Pharmacy £'000	Anticipated Dental £'000	Anticipated GMS £'000	Total RRL £'000			
60. Testing (inc Community Testing)			1,825				1,825			
61. Tracing			2,800				2,800			
62. Mass COVID-19 Vaccination			6,925				6,925			
63. PPE			1,973				1,973			
64. Extended Flu							0			
65. Cleaning Standards			1,840				1,840			
66. Long Covid			578				578			
67. A2: Increased bed capacity specifically related to COVID-19			3,777				3,777			
68. A3: Other Capacity & facilities costs			1,233				1,233			
69. B1: Prescribing changes directly related to COVID symptoms			6,895				6,895			
70. C1: Increased workforce costs as a direct result of the COVID response and IP&C guidance			2,046				2,046			
71. D1: Discharge Support			243				243			
72. D2: Support for National Programmes through Shared Service							0			
73. D3: Other Services that support the ongoing COVID response			880				880			
74. E1: Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS income							0			
75.										
76.										
77.										
78.										
79.										
80.										
81.										
82.										
83.										
84.										
85.										
86.										
87.										
88.										
89.										
90. Total Funding		0	32,621	0	0	0	32,621			

Table F - Statement of Financial Position For Monthly Period		Opening Balance	Closing Balance	Least Closing Balance
To complete from Month 1		Beginning of	End of	End of
		Apr 22	May 22	Mar 23
		£'000	£'000	£'000
Non-Current Assets				
1	Property, plant and equipment			
2	Intangible assets			
3	Trade and other receivables			
4	Other financial assets			
5	Non-current assets sub total			
Current Assets				
6	Inventory			
7	Trade and other receivables			
8	Other financial assets			
9	Cash and cash equivalents			
10	Non-current assets classified as held for sale			
11	Current Assets sub total			
12	TOTAL ASSETS			
Current Liabilities				
13	Trade and other payables			
14	Borrowings (Trust Only)			
15	Other financial liabilities			
16	Provisions			
17	Current Liabilities sub total			
18	NET ASSETS LESS CURRENT LIABILITIES			
Non-Current Liabilities				
19	Trade and other payables			
20	Borrowings (Trust Only)			
21	Other financial liabilities			
22	Provisions			
23	Non-current Liabilities sub total			
24	TOTAL ASSETS EMPLOYED			
FINANCED BY:				
Taxpayers' Equity				
25	General Fund			
26	Resignation Reserve			
27	FSC (Trust only)			
28	Retained earnings (Trust Only)			
29	Other reserves			
30	Total Taxpayers' Equity			
EXPLANATION OF ALL PROVISIONS		Opening Balance	Closing Balance	Closing Balance
		Beginning of	End of	End of
		Apr 22	May 22	Mar 23
31	Clinical negligence			
32	Robbery			
33	Personal injury			
34	Offence fees			
35	Prisoners			
36	Other			
37				
38				
39				
40	Total Provisions		£'000	
ANALYSIS OF WELSH NHS RECEIVABLES (current month)				
41	Welsh NHS Receivables Aged 0 - 10 weeks			
42	Welsh NHS Receivables Aged 11 - 16 weeks			
43	Welsh NHS Receivables Aged 17 weeks and over			
ANALYSIS OF TRADE & OTHER PAYABLES (opening, current & closing)		£'000	£'000	£'000
44	Trade			
45	Revenue			
ANALYSIS OF CASH (opening, current & closing)		£'000	£'000	£'000
46	Cash			
47	Revenue			

Table G - Monthly Cashflow Forecast														
	April £'000	May £'000	June £'000	July £'000	Aug £'000	Sept £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000	Total £'000	
RECEIPTS														
1 WG Revenue Funding - Cash Limit (excluding NCL) - LHB & SHA only	93,127	91,127	91,127	94,127	91,727	94,827	73,127	82,127	87,427	73,627	80,127	42,489	994,966	
2 WG Revenue Funding - Non Cash Limited (NCL) - LHB & SHA only	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(1,926)	
3 WG Revenue Funding - Other (e.g. invoices)	486	121	500	500	500	500	500	500	500	500	500	500	5,817	
4 WG Capital Funding - Cash Limit - LHB & SHA only	14,300	1,300	2,500	2,500	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,151	28,951	
5 Income from other Welsh NHS Organisations	6,226	3,722	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	34,948	
6 Short Term Loans - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
7 PDC - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
8 Interest Receivable - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
9 Sale of Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	
10 Other - (Specify in narrative)	3,645	2,063	2,416	2,129	3,929	2,879	2,879	2,879	3,229	2,579	2,879	3,329	34,735	
11 TOTAL RECEIPTS	117,667	98,206	99,916	101,829	99,329	101,879	79,879	86,879	94,829	86,879	86,879	49,832	1,097,893	
PAYMENTS														
12 Primary Care Services - General Medical Services	5,629	5,169	4,544	4,627	4,627	4,627	4,627	4,627	4,627	4,627	4,627	4,627	56,985	
13 Primary Care Services - Pharmacy Services	3,332	0	1,600	1,900	1,900	1,900	0	1,900	3,000	0	1,900	3,000	19,932	
14 Primary Care Services - Prescribed Drugs and Appliances	11,460	0	6,672	6,500	6,500	13,000	0	6,500	13,000	0	6,500	12,500	82,632	
15 Primary Care Services - General Dental Services	1,471	1,430	1,403	1,450	1,450	1,450	1,450	1,450	1,450	1,450	1,450	1,450	17,334	
16 Non Cash Limited Payments	(117)	(46)	(221)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(127)	(1,550)	
17 Salaries and Wages	41,285	42,438	31,589	43,795	42,671	42,795	42,671	42,671	42,795	42,671	42,671	42,795	501,309	
18 Non Pay Expenditure	42,321	43,947	49,451	38,620	40,100	39,725	39,470	30,220	28,725	29,470	28,720	29,953	426,990	
19 Short Term Loan Repayment - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
20 PDC Repayment - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
21 Capital Payment	13,480	1,044	3,575	2,700	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,151	28,951	
22 Other Items (Specify in narrative)	2,622	871	483	650	550	600	500	500	700	500	500	600	9,026	
23 TOTAL PAYMENTS	121,364	94,716	99,654	99,916	98,291	102,076	79,691	86,381	95,710	79,951	86,641	95,948	1,141,054	
24 Net cash inflow/outflow	(3,697)	3,490	(738)	1,913	1,238	(107)	388	288	(541)	488	38	(46,127)		
25 Balance b/f	1,901	(1,816)	1,674	906	2,819	4,057	3,566	3,954	4,242	3,601	4,089	4,127	(42,009)	
26 Balance c/f	(1,816)	1,674	906	2,819	4,057	3,566	3,954	4,242	3,601	4,089	4,127	(42,009)		

Table H - PSPP													
30 DAY COMPLIANCE													
PROMPT PAYMENT OF INVOICE PERFORMANCE	Target	ACTUAL Q1		ACTUAL Q2		ACTUAL Q3		ACTUAL Q4		YEAR TO DATE		FORECAST YEAR END	
	%	Actual	Variance	Actual	Variance	Actual	Variance	Actual	Variance	Actual	Variance	Forecast	Variance
1 % of NHS Invoices Paid Within 30 Days - By Value	95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%
2 % of NHS Invoices Paid Within 30 Days - By Number	95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%
3 % of Non NHS Invoices Paid Within 30 Days - By Value	95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%
4 % of Non NHS Invoices Paid Within 30 Days - By Number	95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%		-95.0%
10 DAY COMPLIANCE													
PROMPT PAYMENT OF INVOICE PERFORMANCE		ACTUAL Q1		ACTUAL Q2		ACTUAL Q3		ACTUAL Q4		YEAR TO DATE		FORECAST YEAR END	
		Actual		Actual		Actual		Actual		Actual		Actual	
5 % of NHS Invoices Paid Within 10 Days - By Value													
6 % of NHS Invoices Paid Within 10 Days - By Number													
7 % of Non NHS Invoices Paid Within 10 Days - By Value													
8 % of Non NHS Invoices Paid Within 10 Days - By Number													

Table I - Capital Resource / Expenditure Limit Management					20.06.22		
Approved CRL / CEL issued at :					7.6.22		
Ref:	Performance against CRL / CEL	Plan £'000	Actual £'000	Variance £'000	Plan £'000	Forecast £'000	Variance £'000
	Gross expenditure (accrued, to include capitalised finance leases)						
	All Wales Capital Programme:						
	Schemes:						
1	Gangnell - Fire Enforcement works - Phase 1	395	395	0	7,003	7,003	0
2	Withybush - Fire Enforcement works - Phase 1	779	779	0	4,285	4,285	0
3	Neonwales - Phase II - main	221	221	0	808	1,231	423
4	128 - Multi-site projects	0	0	0	373	322	(51)
5	PPH Demolition	374	374	0	1,899	1,899	0
6	Fire Enforcement Works - Withybush Hospital- Decant Ward Fees	68	68	0	188	188	0
7	Withybush - Fire Enforcement works fees - Phase 2	6	6	0	935	935	0
8	National Programme - Decarbonisation	0	0	0	655	652	(3)
9	National Programme - Fire	8	8	0	125	125	0
10	National Programme - Mental Health	0	0	0	420	421	1
11	National Programme - Imaging	40	40	0	214	256	42
12	National Programme - Imaging- CT Scanner PPH	2	2	0	1,385	1,385	0
13	National Programme - Imaging- CT Scanner B&H	4	4	0	1,385	1,385	0
14	National Programme - Imaging- DR Rooms	1	1	0	1,068	1,069	1
15	National Programme - Imaging- Fluoroscopy Rooms	0	0	0	2,820	2,820	0
16	Croes Hands Primary Care scheme	14	14	0	0	75	75
17							
18							
19							
20							154
21							
22							
23							
24							
41							
42	Sub Total	1,911	1,911	0	23,661	24,028	367
43	Discretionary:						
44	IT	34	34	0	200	200	0
45	Equipment	0	0	0	2,126	2,126	0
46	Statutory Compliance	2	2	0	895	895	0
47	Estates	4	4	0	1,254	1,254	0
48	Other	39	39	0	1,614	1,617	3
49	Sub Total	77	77	0	5,289	4,922	(367)
49	Other Schemes:						
50							
51							
52							
53							
54							
55							
56							
57							
58							
59	Sub Total	0	0	0	0	0	0
70	Total Expenditure	1,988	1,988	0	28,950	28,951	1
	Less:						
71	Capital grants:						
72							
73							
74							
75							
76	Sub Total	0	0	0	0	0	0
77	Donations:						
78		0	0	0	0	0	0
79	Asset Disposals:						
80							
81							
82							
83							
84							
85	Sub Total	0	0	0	0	0	0
91	Technical Adjustments						
92	CHARGE AGAINST CRL / CEL	1,988	1,988	0	28,950	28,951	1
93	PERFORMANCE AGAINST CRL / CEL (Under/Over)		(25,033)				(25,033)



Table J - In Year Capital Scheme Profiles

Ref:	All Wales Capital Programme: Schemes:	Project Manager	In Year Forecast		Capital Expenditure Monthly Profile												YTD £'000	Total £'000	Risk Level	
			Min. £'000	Max. £'000	April £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000				
1	Gargelli - Fire Enforcement works - Phase 1	RE	7,003	7,003	115	280	300	626	626	626	626	626	626	626	626	1,099	395	7,003	Low	
2	Withybush - Fire Enforcement works - Phase 1	RE	4,285	4,285	328	451	360	360	360	360	360	360	360	360	360	268	779	4,285	Low	
3	Neonates - Phase II - main	KJ	1,231	1,231	126	94	52	14	14	14	14	21	23	14	13	831	221	1,231	Low	
4	IGS - Multi-site projects	RE	322	322	0	0	0	41	41	41	41	41	41	41	32	0	322	0	Low	
5	PPH Demountable	KJ	1,899	1,899	360	(15)	503	503	518	0	0	0	0	0	0	0	374	1,899	Low	
6	Fire Enforcement Works - Withybush Hospital- Decant Ward Fees	RE	188	188	3	65	65	55	0	0	0	0	0	0	0	0	65	188	Low	
7	Withybush - Fire Enforcement works less - Phase 2	RE	935	935	0	6	0	0	200	200	200	200	129	0	0	0	0	6	935	Low
8	National Programme - Decontamination	RE	632	632	0	0	0	220	412	0	0	0	0	0	0	0	0	0	632	Low
9	National Programme - Fire	RE	125	125	5	3	31	31	31	0	0	0	23	0	0	0	0	8	125	Low
10	National Programme - Mental Health	LC	421	421	0	0	38	38	139	130	37	39	0	0	0	0	0	0	421	Low
11	National Programme - Imaging	GR	256	256	16	24	99	99	17	0	0	0	0	0	0	0	0	40	256	Low
12	National Programme - Imaging - CT Scanner PPH	GR	1,385	1,385	0	2	0	0	0	0	0	394	394	394	201	0	0	2	1,385	Low
13	National Programme - Imaging - CT Scanner BPH	GR	1,385	1,385	0	4	0	0	394	394	394	199	0	0	0	0	0	4	1,385	Low
14	National Programme - Imaging - DR Rooms	GR	1,069	1,069	0	1	0	0	89	178	267	244	165	68	68	0	0	1	1,069	Low
15	National Programme - Imaging - Fluoroscopy Rooms	GR	2,820	2,820	0	0	0	100	0	0	0	328	328	328	328	1,410	0	2,820	Low	
16	Cross Halls Primary Care scheme	RD	75	75	0	14	7	7	7	7	7	7	7	7	7	0	0	14	75	Low
17																	0	0		
18																	0	0		
19																	0	0		
20																	0	0		
21																	0	0		
22																	0	0		
23																	0	0		
24																	0	0		
25																	0	0		
26																	0	0		
34	Sub Total		24,029	24,029	992	928	1,456	2,095	2,847	1,950	1,948	2,459	2,086	1,837	1,834	3,608	1,911	24,029		
Discretionary:																				
35	I.T.	AT	200	200	0	34	10	0	80	0	10	50	0	10	36	0	34	200	Low	
36	Equipment	GR	2,126	2,126	0	0	762	36	188	236	519	104	133	36	36	73	0	2,126	Low	
37	Statutory Compliance	RE	895	895	0	2	29	20	18	44	66	67	20	147	268	205	2	895	Low	
38	Estates	RE	1,254	1,254	1	3	109	68	42	8	55	25	51	7	18	865	4	1,254	Low	
39	Other	Various	447	447	2	30	45	45	45	45	45	45	45	45	45	45	0	38	447	Low
40	Sub Total		4,922	4,922	3	74	955	170	344	334	696	42	281	249	245	424	1,145	77	4,923	
Other Schemes:																				
41																	0	0		
42																	0	0		
43																	0	0		
44																	0	0		
45																	0	0		
46																	0	0		
47																	0	0		
48																	0	0		
49																	0	0		
61	Sub Total		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
62	Total Capital Expenditure		28,951	28,951	995	1,003	2,411	2,265	3,191	2,284	2,643	2,740	2,335	2,083	2,258	4,754	1,988	28,951		

Table K - Capital Disposals									
A: In Year Disposal of Assets									
	Description	Date of Ministerial Approval to Dispose (Land & Buildings only) MM/YY (text format, e.g. Apr 22)	Date of Ministerial Approval to Retain Proceeds > £5m MM/YY (text format, e.g. Apr 22)	Date of Disposal MM/YY (text format, e.g. Feb 23)	NBV £'000	Sales Receipts £'000	Cost of Disposals £'000	Gain/ (Loss) £'000	Comments
1								0	
2								0	
3								0	
4								0	
5								0	
6								0	
7								0	
8								0	
9								0	
10								0	
11								0	
12								0	
13								0	
14								0	
15								0	
16								0	
17								0	
18								0	
19	Total for in-year				0	0	0	0	

Table M - Debtors Schedule								
11 weeks before end of May 22 = 15 March 2022								
17 weeks before end of May 23 = 01 February 2023								
Debtor	Inv #	Inv Date	Orig Inv £	Outstand. Inv £	Valid Entry	>11 weeks late <17 weeks	Over 17 weeks	Arbitration Due Date
			0.00	0.00		0.00	0.00	
Invoices paid since the end of the month								
Total outstanding as per M01 submission date						0.00	0.00	

Table N - General Medical Services  
Operating Expenditure - ring fenced GMS budget

SUMMARY OF GENERAL MEDICAL SERVICES FINANCIAL POSITION						Year to Date
	LINE NO.	WG Allocation £000's	Current Plan £000's	Forecast Outturn £000's	Variance £000's	£000's
Global Sum	1					
Medical support payment	2					
Total Global Sum and MPD	3					
GPAT Aspirator Payments	4					
GPAT Assessment Payments	5					
GPAT Access Assessment Payments	6					
Total GPAT	7					
GPAT Enhanced Services (To equal data in Section A (i) Line 31)	8					
National Enhanced Services (To equal data in Section A (ii) Line 41)	9					
Local Enhanced Services (To equal data in Section A (iii) Line 94)	10					
Total Enhanced Services (To equal data in section A Line 95)	11					
GPAT Administration (To equal data in Section B Line 100)	12					
GPAT Administration (To equal data in Section C Line 100)	13					
GPAT Administration (To equal data in Section C Line 100)	14					
GPAT Administration (To equal data in Section C Line 100)	15					
GPAT Administration (To equal data in Section C Line 100)	16					
GPAT Administration (To equal data in Section C Line 100)	17					
SUPPLEMENTARY INFORMATION						
Directed Enhanced Services Section A (i)						
Learning Disabilities	18					
Chronic Disease Management Scheme	19					
Minor Injuries	20					
Infectious & Pneumococcal Immunisation Scheme	21					
Services for Vulnerable Patients	22					
Minor Surgical Fees	23					
GPAT Administration (To equal data in Section B Line 100)	24					
GPAT Administration (To equal data in Section C Line 100)	25					
Care Homes	26					
GPAT Administration (To equal data in Section B Line 100)	27					
GPAT Administration (To equal data in Section C Line 100)	28					
GPAT Administration (To equal data in Section C Line 100)	29					
GPAT Administration (To equal data in Section C Line 100)	30					
GPAT Administration (To equal data in Section C Line 100)	31					
TOTAL Directed Enhanced Services (must equal line 8)						
National Enhanced Services Section A (ii)						
GPAT Administration (To equal data in Section B Line 100)	32					
GPAT Administration (To equal data in Section C Line 100)	33					
GPAT Administration (To equal data in Section C Line 100)	34					
GPAT Administration (To equal data in Section C Line 100)	35					
GPAT Administration (To equal data in Section C Line 100)	36					
GPAT Administration (To equal data in Section C Line 100)	37					
GPAT Administration (To equal data in Section C Line 100)	38					
GPAT Administration (To equal data in Section C Line 100)	39					
GPAT Administration (To equal data in Section C Line 100)	40					
GPAT Administration (To equal data in Section C Line 100)	41					
TOTAL National Enhanced Services (must equal line 9)						
Local Enhanced Services Section A (iii)						
GPAT Administration (To equal data in Section B Line 100)	42					
GPAT Administration (To equal data in Section C Line 100)	43					
GPAT Administration (To equal data in Section C Line 100)	44					
GPAT Administration (To equal data in Section C Line 100)	45					
GPAT Administration (To equal data in Section C Line 100)	46					
GPAT Administration (To equal data in Section C Line 100)	47					
GPAT Administration (To equal data in Section C Line 100)	48					
GPAT Administration (To equal data in Section C Line 100)	49					
GPAT Administration (To equal data in Section C Line 100)	50					
GPAT Administration (To equal data in Section C Line 100)	51					
GPAT Administration (To equal data in Section C Line 100)	52					
GPAT Administration (To equal data in Section C Line 100)	53					
GPAT Administration (To equal data in Section C Line 100)	54					
GPAT Administration (To equal data in Section C Line 100)	55					
GPAT Administration (To equal data in Section C Line 100)	56					
GPAT Administration (To equal data in Section C Line 100)	57					
GPAT Administration (To equal data in Section C Line 100)	58					
GPAT Administration (To equal data in Section C Line 100)	59					
GPAT Administration (To equal data in Section C Line 100)	60					
GPAT Administration (To equal data in Section C Line 100)	61					
GPAT Administration (To equal data in Section C Line 100)	62					
GPAT Administration (To equal data in Section C Line 100)	63					
GPAT Administration (To equal data in Section C Line 100)	64					
GPAT Administration (To equal data in Section C Line 100)	65					
GPAT Administration (To equal data in Section C Line 100)	66					
GPAT Administration (To equal data in Section C Line 100)	67					
GPAT Administration (To equal data in Section C Line 100)	68					
GPAT Administration (To equal data in Section C Line 100)	69					
GPAT Administration (To equal data in Section C Line 100)	70					
GPAT Administration (To equal data in Section C Line 100)	71					
GPAT Administration (To equal data in Section C Line 100)	72					
GPAT Administration (To equal data in Section C Line 100)	73					
GPAT Administration (To equal data in Section C Line 100)	74					
GPAT Administration (To equal data in Section C Line 100)	75					
GPAT Administration (To equal data in Section C Line 100)	76					
GPAT Administration (To equal data in Section C Line 100)	77					
GPAT Administration (To equal data in Section C Line 100)	78					
GPAT Administration (To equal data in Section C Line 100)	79					
GPAT Administration (To equal data in Section C Line 100)	80					
GPAT Administration (To equal data in Section C Line 100)	81					
GPAT Administration (To equal data in Section C Line 100)	82					
GPAT Administration (To equal data in Section C Line 100)	83					
GPAT Administration (To equal data in Section C Line 100)	84					
GPAT Administration (To equal data in Section C Line 100)	85					
GPAT Administration (To equal data in Section C Line 100)	86					
GPAT Administration (To equal data in Section C Line 100)	87					
GPAT Administration (To equal data in Section C Line 100)	88					
GPAT Administration (To equal data in Section C Line 100)	89					
GPAT Administration (To equal data in Section C Line 100)	90					
GPAT Administration (To equal data in Section C Line 100)	91					
GPAT Administration (To equal data in Section C Line 100)	92					
GPAT Administration (To equal data in Section C Line 100)	93					
GPAT Administration (To equal data in Section C Line 100)	94					
TOTAL Local Enhanced Services (must equal line 10)						
TOTAL Enhanced Services (must equal line 11)						

GENERAL MEDICAL SERVICES  
Operating Expenditure

		WG Allocation	Current Plan	Forecast Outturn	Variance	Year to Date
LHB Administered		£000's	£000's	£000's	£000's	£000's
Section B		LINE NO.				
General						
Doctors Retention Scheme Payments		87				
Locum Allowances - costs of adoption, paternity & maternity		88				
Locum Allowances - Cover for Sick Leave		89				
Locum Allowances - Cover for Suspended Doctors		90				
Prolonged Sick Leave		101				
Recruitment and Retention (including Golden Hello)		102				
Appraisal - Appraiser Costs		103				
Primary Care Development Scheme		104				
Partnership Payments - GP partners		105				
Partnership Payments - Non GP Partners		106				
Supply of supplies & materials		107				
Other (please provide detail below, this should reconcile to line 128)		108				
TOTAL LHB Administered (must equal line 132)		109				
Analysis of Other Payments (line 108)		LINE NO.	£000's	£000's	£000's	£000's
Additional Managed Practice costs (costs in excess of Global SumMPPS)		110				
GP checks		111				
GP costs payments		112				
LHB Locally group costs		113				
Managing Practice costs (LHB employed staff working in GP practices to improve GP services)		114				
Primary Care Initiatives		115				
Salaries GP costs		116				
Stationery & Distribution		117				
Training		118				
Transportation fees		119				
Practice/management payments to GP practices		120				
Parking and Storage		121				
Postage		122				
GP Staff Payments		123				
		124				
		125				
Other		126				
TOTAL of Other Payments (must equal line 108)		127				
Premises		Section C	LINE NO.	£000's	£000's	£000's
National Beds		128				
Actual Beds Health Centres		129				
Actual Beds Clinics		130				
Cost Rent		131				
Contract Winter Trade Refuse		132				
Rates, Water, sewerage etc		133				
Health Centre Charges		134				
Improvement Grants		135				
All other Premises (please detail below which should reconcile to line 146)		136				
TOTAL Premises (must equal line 137)		137				
Analysis of Other Premises (line 137)		LINE NO.	£000's	£000's	£000's	£000's
CV Fees		138				
		139				
		140				
		141				
		142				
		143				
		144				
		145				
TOTAL of Other Premises (must equal line 137)		146				
Water/sewerage item		147				
Enhanced Services included above but in dispute with LMC (TOTAL)		148				
Enhanced Services included above but not yet formally agreed LMC						

GENERAL MEDICAL SERVICES  
Dispensing

		WG Allocation	Current Plan	Forecast Outturn	Variance	Year to Date
Dispensing Data		£000's	£000's	£000's	£000's	£000's
Section B		LINE NO.				
Cost of Drugs and Appliances, after discounts and plus container allowance (and plus VAT where applicable)						
Dispensing Section		149				
Prescription Medical Practitioners - Personal Administration		150				
Dispensing Section Locality Payment		151				
Professional Fees and on-cost						
Dispensing Section		152				
Prescription Medical Practitioners - Personal Administration		153				
TOTAL DISPENSING DATA (must equal line 16)		154				

Table O - General Dental Services  
Operating Expenditure from the revenue allocation for the dental contract

SUMMARY OF DENTAL SERVICES FINANCIAL POSITION		WG Allocation	Current Plan	Forecast Outturns	Variance	Year to Date
Expenditure activities included in a DSS contract and / or PDS agreement	LINE NO.	£000's	£000's	£000's	£000's	£000's
Gross Contract Value - Personal Dental Services	1					
Gross Contract Value - General Dental Services	2					
Emergency Dental Services (inc Out of Hours)	3					
Additional Access	4					
Business Hours	5					
Domiliary Services	6					
Making Business etc.	7					
Isolation services including GAs	8					
Security payments	9					
Employer's Superannuation	10					
Other staff	11					
OTHER						
PLEASE						
DETAIL						
BELOW						
TOTAL DENTAL SERVICES EXPENDITURE	13					
REVENUE. This includes payments made under other arrangements e.g. GA under an SLA and DSS, plus	LINE NO.	£000's	£000's	£000's		£000's
Emergency Dental Services (inc Out of Hours)	14					
Additional Access	15					
Isolation services including GAs	16					
Continuing professional development	17					
Comprehensive Health / Hygiene B	18					
Green Am Sybts - Oral Health in care homes	19					
Refuse of patient charges	20					
Disputes to Bites	21					
Other Community Dental Services	22					
General Foundation Training/Operational Training	23					
DSS/CDS checks	24					
Health Board staff costs associated with the delivery / monitoring of the dental contract	25					
Oral Surgery	26					
Cybersecurity	27					
Special care dentistry e.g. WHC0216502	28					
Oral Health Prevention Education	29					
Insurance verification in dental practices	30					
Alcohol Awareness	31					
COS	32					
Training Income	33					
Dental Technology	34					
Other Income	35					
Dental Staff Payment	36					
	37					
	38					
	39					
	40					
	41					
	42					
	43					
TOTAL OTHER (must equal line 13)						
RECEIPTS						
TOTAL DENTAL SERVICES INCOME (Enter as a negative value)	44					

# YTD Financial Performance and EoY Forecast Month 2 2022/23

## Health Board's draft Financial Plan is to deliver a deficit of £25.0m, after savings of £29.4m.


Financial position	Month 1 £'m	Month 2 £'m	YTD £'m	EOY £'m
Planned deficit	2.1	2.1	4.2	25.0
Undelivered Savings plans	1.4	1.6	3.0	17.0
Operational variance <i>(see third bullet point for risk)</i>	0.9	0.6	1.5	0.0
COVID-19 expenditure	2.9	3.3	6.2	32.6
<b>Operational variance before WG COVID-19 funding</b>	<b>7.3</b>	<b>7.6</b>	<b>14.9</b>	<b>74.6</b>
WG COVID-19 funding: 'Programme' costs	(1.3)	(1.6)	(2.9)	(15.1)
WG COVID-19 funding: 'Other' costs	0.0	0.0	0.0	(1.1)
WG COVID-19 funding: 'Transitional' costs	(1.6)	(1.7)	(3.3)	(16.4)
<b>Reported financial position</b>	<b>4.4</b>	<b>4.3</b>	<b>8.7</b>	<b>42.0</b>

- Confirmation received of WG funding to match costs of COVID-19 programmes (Tracing, Testing, Mass Vaccinations and PPE), and initial WG guidance received to assume funding provided to offset transitional costs of COVID-19 (£16.4m) and the Exceptional Energy, Health and Social Care Levy and Real Living Wage commissioned services costs of £12.0m.
- The Health Board is forecasting a financial outturn of £42.0m, which is £17.0m higher than the planned deficit of £25.0m. This is due to there being an inadequate level of assurance at this stage around the identification of a further £17.0m of savings schemes deliverable within the current financial year.
- Further risk to current £42.0m forecast in relation to operational pressures experienced in Month 1 and 2; as a minimum there is a need to recover the £1.5m operational variation during the remainder of the year, and there is the potential for a continuation of this trend without full mitigation, which at this stage is assessed as c.£11m.
- Work is ongoing to evidence the additional activity to provide WG with assurance over the utilisation of ring fenced recovery funding.




# Executive Summary: Key drivers of in-month position

## In-month variance by Directorate




## In-month variance by Subjective




Directorate over-spends were primarily driven by:

- **Savings non-delivery £1.6m:** in-month value of savings undelivered by the organisation;
- **Unscheduled Care £1.7m:** Continuation of site pressures where high levels of vacancies and activity are resulting in high variable pay expenditure across all four acute sites;
- **Public Health £1.3m:** Primarily driven by costs associated with the Health Board's on-going response to COVID-19 in regards to TTP and Mass Vaccinations.

## YTD actual by Subjective (COVID-19 only)



# End of Year Financial Position: 2022/23





Run rate pressures (additional £8.8m from those expected in the submitted financial plan) are building across several operational areas, with others areas spending in line with budgets, i.e. not delivering the underspends as seen in previous years. If this trend continues without full mitigation:

- there is a risk to the current forecast of c.£11m; and
- the planned budgetary realignment to formalise the requirements of the Nurse Staffing Act (25A & Other wards) will be impeded.

A revised financial plan is being developed for submission at the end of Q1; this will present a revised financial deficit.

Transitional and Programme COVID-19 schemes are in line with the IP&C agreed plans which are currently under review following the WG de-escalation guidance published in May 2022; the expectation is that there will be an accelerated de-commissioning of schemes and potentially a re-classification into Recovery of some schemes providing additional capacity, which may impact the overall forecast. There is also an expectation from WG that Prescribing price increases of £4.4m currently attributed to COVID-19 will need to be realigned to the core position and therefore not be eligible for WG funding.

# End of Year Financial Position: 2022/23 Expenditure Profile



## Pay

The profile of forecast staffing costs is driven by:

- Continued acute pressures, particularly within Emergency Departments resulting in a continued reliance on Agency to backfill vacancies and sickness;
- Additional resource to deliver step up in Urgent and Emergency Care plans, implementation of Integrated Localities plans and PACU in PPH;
- Additional resource to deliver additional capacity within Elective Recovery plans;
- No assumptions yet included in the Month 2 forecast in respect of any potential inflationary pay awards. While this will impact pay actual profiles, the impact is expected to be fully funded by WG.

## Non-Pay

The step up in actual expenditure in the later part of the year is primarily due to the revised Theatre plans within the Planned Care directorate where they predict returning to 100% activity from Month 6. Non pay costs are also anticipated to increase due to the exceptional utility costs being incurred across the Health Board premises.

A robust IP&C led assessment of the planned COVID-19 transitional response will underpin the operational response required for the remainder of the year. At present, the following costs are being forecasted, with the following slides identifying responses required dependant on theme.

Directorate £'k	Cleaning Standards	Increased Bed capacity	Other Capacity & Facilities	Prescribing & Drugs Regimes	Increased Workforce	Discharge Support	Other support services	Total
Health Board Wide	-	-	-	468	1,707	-	-	2,175
Medicines Management	-	-	-	4,382	-	-	-	4,382
Facilities	1,842	-	589	-	-	-	-	2,431
Carmarthenshire System	-	1,617	12	1,007	-	-	-	2,636
Ceredigion System	-	733	23	-	-	-	-	756
Director of Operations	-	-	545	-	64	230	-	839
Oncology	-	-	-	754	-	-	-	754
Pembrokeshire System	-	1,428	-	-	36	14	-	1,478
Women & Children	-	-	-	-	-	-	387	387
Pathology	-	-	-	284	-	-	-	284
Planned Care	-	-	66	-	240	-	-	306
<b>Total</b>	<b>1,842</b>	<b>3,778</b>	<b>1,235</b>	<b>6,895</b>	<b>2,407</b>	<b>244</b>	<b>387</b>	<b>16,428</b>

- Of the £29.4m requirement, £12.4m have been identified as Green/Amber schemes, as a minimum on a non-recurrent basis; only a small number are currently assessed as recurrent, with a full year effect of £0.5m. There is a significant risk that the underlying deficit of £53.9m will continue if recurrent savings schemes of £28.9m are not identified in-year.
- In-month delivery of £0.9m, which is in line with the Green/Amber savings scheme plans.
- The Savings forecast has remained unchanged in Month 2 compared to what was identified in Month 1.

Savings Delivery	Monthly Performance			Year to Date Performance			Annual 2022-23 & Full Year Effect			
	Mth Plan	Mth Act	Mth Var	YTD Plan	YTD Act	YTD Var	Year Plan	Year Act	Year Var	FYE Plan
Recurrent	11	11	0	19	19	0	304	278	26	469
FACILITIES	0	0	0	0	0	0	174	148	26	337
DIGITAL	11	11	0	19	19	0	130	130	0	133
Non Recurrent	858	858	0	1,864	1,864	0	12,061	12,061	0	0
HEALTH BOARD WIDE	853	853	0	1,853	1,853	0	12,026	12,026	0	0
FINANCE	6	6	0	12	12	0	35	35	0	0
Grand Total	869	869	0	1,884	1,884	0	12,366	12,339	26	469

# Appendices

## Red Schemes – Decommissioning date to be confirmed

Directorate	Theme	Scheme	£'000
Facilities	A. Capacity and Facilities	Maintenance remediation	28
		Ongoing non-pay costs	308
Carmarthenshire System	A. Capacity and Facilities	AMAU Red pathway	639
		Portacabin hire	12
		PPH additional 21 beds	432
		Red Pathway Padarn ward	83
		Amman Valley 8 beds	262
	B. Prescribing and Drug Regimes	Move to homecare treatment	1,007
Ceredigion System	A. Capacity and Facilities	Accommodation for Therapies	23
		Designated COVID ward in Y Banwy	512
		Red Pathway 3 rooms in ED	50
Pembrokeshire System	A. Capacity and Facilities	Addition COVID beds	1,428
	C. Workforce	Red / Green A&E staffing	37
	D. Support Services	District nursing	13

- Red schemes have no current guidance associated to warrant continuing on the grounds of COVID-19 guidance / policy
- All schemes require an operational assessment and to confirm a decommissioning date, that should be in the current financial year
- Following confirmation of decommissioning date, operational teams will be expected to implement actions to ensure the activities are decommissioned in line with the date included within the Q1 plan re-submission
- These will form part of the monthly reporting progress update for the remainder of the year

## Red Schemes – Decommissioning date to be confirmed

Directorate	Theme	Scheme	£'000
Medicines Mgt	B. Prescribing and Drug Regimes	April 2020 Cat M price increase	4,382
Dir. of Operations	A. Capacity and Facilities	Dura Park	182
		Equipment storage	362
	D. Support Services	Addition WAST vehicle	230
Oncology	B. Prescribing and Drug Regimes	Treatment regime changes	755
Pathology	B. Prescribing and Drug Regimes	Haematology regime changes	284
Health Board Wide	C. Workforce	COVID-19 absence cover	1,396
		Pay enhancement (April only)	311
<b>Total Red</b>			<b>12,736</b>

- Red schemes have no current guidance associated to warrant continuing on the grounds of COVID-19 guidance / policy
- All schemes require an operational assessment and to confirm a decommissioning date, that should be in the current financial year
- Following confirmation of decommissioning date, operational teams will be expected to implement actions to ensure the activities are decommissioned in line with the date included within the Q1 plan re-submission
- These will form part of the monthly reporting progress update for the remainder of the year



## Amber Schemes – Leadership team direction required

Directorate	Theme	Scheme	£'000
Facilities	A. Capacity and Facilities	Enhanced cleaning standards	1,842
		Requested support from services	253
Carmarthenshire System	A. Capacity and Facilities	Immediate care MDT beds in Llys y Bryn Ty Pili Pala unit – 14 beds	200
Ceredigion System	A. Capacity and Facilities	Tregaron addition 8 beds	171
Dir. of Operations	C. Workforce	Central engineering maintenance	64
Women & Children	D. Support Services	Enhanced PACU service	388
Health Board Wide	B. Prescribing and Drug Regimes	Secondary Care COVID-19 drugs	468
<b>Total Amber</b>			<b>3,386</b>

- Amber schemes either have mixed interpretation of the guidance, or are no longer required from a COVID-19 perspective, but are likely to impact current patient flow pressures if decommissioned
- An Executive and Operations Leadership team direction is required to provide directorates with the clarity on whether they should continue to provide the response, or to decommission it from a specific point in time
- Confirmation, either way, is required to be included in the Q1 plan re-submission from each directorate who continue to provide the responses

## Green Schemes – To decommission or transfer to Recovery

Directorate	Theme	Scheme	£'000
Planned Care	A. Capacity and Facilities	Single use ENT scopes	66
	C. Workforce	PPH green pathway for Cancer Services for General Surgery and Colorectal	240
<b>Total Green</b>			<b>306</b>

- Green schemes have no current guidance associated to warrant continuing on the grounds of COVID-19 guidance / policy
- The directorate will need to confirm if the response will either be decommissioned, confirming the date at which they will be, or move them into the Recovery plan if they are delivering additional activity
- Confirmation, either way, is required to be included in the Q1 plan re-submission from each directorate who continue to provide the responses